Perrigo Company Plc Ireland (PRGO)

Perrigo Announces Appointment of Two New Independent Directors to BoardJune 30, 2026 4:25 PM
PR Newswire (US) DUBLIN, June 30, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo"), a leading provider of consumer health products, today announced that its Board of Directors has appointed Salman Amin and Omer Gajial as independent directors, effective June 30, 2026. "We are pleased to welcome Salman and Omer to Perrigo's Board," said Orlando D. Ashford, Chair of Perrigo's Board of Directors. "Both bring deep experience across consumer products, retail, and digital transformation, along with a strong track record of driving growth and operational excellence. Their perspective will be valuable as we continue to advance Perrigo's strategic priorities."Salman AminMr. Amin, age 66, is an experienced executive with more than 30 years in the global consumer products industry. He most recently served as Chief Executive Officer of pladis Global, where he led a multi-year transformation that delivered sustained revenue growth and improved profitability.Previously, Mr. Amin served as Chief Operating Officer of the Global Commercial Division at SC Johnson and held senior leadership roles at PepsiCo and Procter & Gamble.Omer GajialMr. Gajial, age 52, is a seasoned executive with extensive experience in retail, e-commerce and consumer health. He currently serves as Chief Executive Officer of GoTo Foods, a franchisor and operator of more than 7,000 restaurant and retail locations globally across multiple brands.Prior to this role, Mr. Gajial served as Executive Vice President and Chief Merchandising & Digital Officer at Albertsons Companies.About PerrigoPerrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers trusted self-care solutions that can be used without the need for a prescription, ensuring accessibility and choice for consumers across molecules, dosage forms, and value tiers.Perrigo's unique business model leverages its complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.For more information, visit www.perrigo.com.Forward-Looking StatementsCertain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements regarding Perrigo's expectations about the contributions of its new directors and the advancement of its strategic priorities. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, general economic conditions and other factors described in Perrigo's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent filings. Perrigo undertakes no obligation to update any forward-looking statements, except as required by law.Perrigo ContactsEric Jacobson, Vice President, Global Investor Relations
eric.jacobson@perrigo.com Nick Gallagher, Associate Director, Global Investor Relations
nicholas.gallagher@perrigo.com View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-announces-appointment-of-two-new-independent-directors-to-board-302814957.htmlSOURCE Perrigo Company plc Original: Perrigo Announces Appointment of Two New Independent Directors to Board

Perrigo Announces Leadership TransitionJune 8, 2026 4:18 PM
PR Newswire (US) Albert A. Manzone Appointed Interim President and CEOPatrick Lockwood-Taylor Resigns as President and CEO and as a Member of the BoardDUBLIN, June 8, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that its Board of Directors has appointed Albert A. Manzone, a member of the Company's Board, as Interim President and Chief Executive Officer, effective immediately. The Board has initiated a comprehensive search process to identify a permanent successor. Patrick Lockwood-Taylor has resigned as President and CEO, and as a member of the Board, effective immediately. This resignation follows a determination by the Board of Directors that certain personal conduct by Mr. Lockwood-Taylor was not consistent with the Company's Code of Conduct and core values. The conduct did not involve the Company's business, strategy, operations, financial reporting, or results of operations.Orlando D. Ashford, Chair of Perrigo's Board of Directors, said, "Perrigo's core values are foundational to how we operate, and the Board expects all colleagues – especially our senior leaders – to uphold those standards at all times. The Board acted decisively and has full confidence in Albert, who brings more than 30 years of global leadership experience and a proven track record of transforming businesses at inflection points and creating value as well as deep knowledge of our business, people, and self-care platform. The Company has made significant progress in advancing our strategy in recent years, stabilizing and streamlining the business and implementing our new commercial operating model and the Board remains confident in Perrigo's outlook. As we move forward, we believe Albert is the right leader to guide Perrigo through this transition and work with the broader leadership team to continue strengthening our company and deliver enhanced value for shareholders."Albert A. Manzone, Interim President and CEO of Perrigo, said, "I have served on Perrigo's Board since 2022, and I know this company well — its self-care platform, its people, and the clear progress we have made on our strategy. My priority as interim CEO is continuity: to keep that strategy on course and to support a talented leadership team as we sustain our momentum on value creation. I look forward to working closely with the Board and the team in the months ahead."Perrigo also reaffirmed its full-year 2026 outlook provided in its first quarter 2026 earnings press release issued on May 6, 2026, including All In net sales growth of (5.5)% to (1.5)%, All In adjusted EPS of $2.00 to $2.30, Core net sales growth of (3.0)% to +1.0% and Core adjusted EPS of $2.25 to $2.55.About Albert A. ManzoneAlbert A. Manzone is a global executive with more than 30 years of leadership experience across consumer goods, consumer health, luxury and hospitality. He has led businesses at global scale, with a track record of transforming companies at inflection points and creating value. He has served as a member of the Perrigo Board of Directors since 2022. Most recently, he was Deputy Chief Executive Officer of Monte-Carlo Société des Bains de Mer, a premier luxury hospitality group, where he drove operational performance and strengthened the leadership team across three consecutive record years. Previously, he served as Chief Executive Officer of Whole Earth Brands, a global food company. Earlier in his career, he was President Europe at Oettinger Davidoff AG and held senior leadership roles at Novartis Consumer Health, W.M. Wrigley Jr. Company, PepsiCo, and McKinsey & Company. He currently serves as a director at Syntec Optics Holdings (NASDAQ: OPTX). He holds an MBA from the Kellogg School of Management at Northwestern University and a postgraduate degree in international business from Sorbonne University.About PerrigoPerrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.For more information, visit www.perrigo.com.Forward-Looking StatementsCertain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "forecast," "predict," "potential" or the negative of those terms or other comparable terminology. We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control, including: the impact of the leadership transition described herein on our relationships with investors, employees, suppliers, wholesalers, lenders and other stakeholders; our ability to complete the proposed divestment of the Dermacosmetics branded business, receipt of works council and regulatory approval regarding the transaction, performance by counterparties to the transaction and the likelihood of satisfying the deferred payment milestones associated with the transaction, supply chain impacts on our business, including those caused or exacerbated by armed conflict, trade and other economic sanctions and/or disease; general economic, credit, and market conditions; increased or new tariffs by the U.S. or foreign governments (and any retaliatory or reciprocal tariffs) and changes in global trade relations; the impact of the war in Ukraine and any escalation thereof, including the effects of economic and political sanctions imposed by the United States, United Kingdom, European Union, and other countries related thereto; the outbreak or escalation of conflict in other regions where we do business, including the ongoing conflict and social, political and economic environment in Israel and the broader Middle East; current and future impairment charges, if we determine that the carrying amount of specific assets may not be recoverable from the expected future cash flows of such assets; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than we do; pricing pressures from customers and consumers; resolution of uncertain tax positions and any litigation relating thereto, ongoing or future government investigations and regulatory initiatives; uncertainty regarding our ability to obtain and maintain our regulatory approvals; potential costs and reputational impact of product recalls or sales halts; potential adverse changes to U.S. and foreign tax, healthcare and other government policy; the effect of epidemic or pandemic disease; the timing, amount and cost of any share repurchases (or the absence thereof) and/or any refinancing of outstanding debt at or prior to maturity; fluctuations in currency exchange rates and interest rates; receipt of potential earnout payments in connection with the sale of the HRA Rare Diseases Business and the risk that potential costs or liabilities incurred or retained in connection with this transaction may exceed our estimates or adversely affect our business or operations; the risk that potential costs or liabilities incurred or retained in connection with the sale of our Rx business may exceed our estimates or adversely affect our business or operations; the consummation and success of other announced and unannounced acquisitions or dispositions, and our ability to realize the desired benefits thereof; and our ability to execute and achieve the desired benefits of announced cost-reduction efforts and other strategic initiatives and investments, including our ability to achieve the expected benefits from our ongoing restructuring programs and strategic review processes described herein. Adverse results with respect to pending litigation could have a material adverse impact on our operating results, cash flows and liquidity, and could ultimately require the use of corporate assets to pay damages, reducing assets that would otherwise be available for other corporate purposes. These and other important factors, including those discussed in our Form 10-K for the year ended December 31, 2025, and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.Perrigo ContactsEric Jacobson, Vice President, Global Investor Relations
eric.jacobson@perrigo.com Nick Gallagher, Associate Director, Global Investor Relations
nicholas.gallagher@perrigo.com View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-announces-leadership-transition-302794395.htmlSOURCE Perrigo Company plc Original: Perrigo Announces Leadership Transition

Perrigo to Present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce ConferenceMay 26, 2026 8:30 AM
PR Newswire (US) DUBLIN, May 26, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of consumer products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference on Tuesday, June 9th at 10:30 AM EDT.  Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.About PerrigoPerrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers trusted self-care solutions that can be used without the need for a prescription, ensuring accessibility and choice for consumers across molecules, dosage forms, and value tiers.Perrigo's unique business model leverages its complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.For more information, visit www.perrigo.com.Forward-Looking StatementsThis press release includes, and the matters discussed in Perrigo's presentation at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference will include certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements involve known and unknown risks, uncertainties and other factors—many of which are beyond the Company's control—that may cause the actual results, performance or achievements of the Company to be materially different from its current expectations, assumptions, estimates and projections. Interested persons are urged to consult the Company's filings with the United States Securities and Exchange Commission, available at https://investor.perrigo.com/sec-filings, for a discussion of the Company's business and financial condition and certain material trends, risks, uncertainties and other factors relating thereto, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2025.Perrigo ContactEric Jacobson, Vice President, Global Investor Relations
(616) 886-0375, eric.jacobson@perrigo.comNick Gallagher, Associate Director, Global Investor Relations
(269) 686-3238, nicholas.gallagher@perrigo.com View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-to-present-at-the-oppenheimer-26th-annual-consumer-growth--e-commerce-conference-302781685.htmlSOURCE Perrigo Company plc Original: Perrigo to Present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference

Perrigo Reports First Quarter 2026 Financial Results From Continuing OperationsMay 6, 2026 6:30 AM
PR Newswire (US) Mitigating category headwinds with market share gains through implementation of Three-S plan.Specialty Care segment achieved net sales and segment operating income growth, led by continued momentum in Compeed®, Opill®, and ellaOne® brands.Completed divestiture of Dermacosmetics business after quarter end; upfront proceeds of approximately €306 million will support debt reduction.Maintained full-year 2026 outlook with continued expectation for second half improvement.DUBLIN, May 6, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced financial results from continuing operations for the first quarter ended March 28, 2026. "Our first quarter results reflect tangible progress as we continue to transform Perrigo into a more focused, disciplined, and consistent business," said President and CEO Patrick Lockwood-Taylor. "Despite a challenging operating environment, we are advancing a clear plan to address the factors within our control. Our Three-S plan and shift to a category-led operating model are strengthening execution and accountability, and the momentum we are seeing in areas such as U.S. Store Brand and Women's Health are encouraging. We also continue to simplify and streamline the organization through disciplined portfolio actions, including the sale of our Dermacosmetics business, with proceeds expected to be used to support debt reduction."We are maintaining our full-year guidance, supported by clear, quantifiable factors expected to drive improvement in the second half of the year. We recognize that the environment is dynamic, and we are monitoring potential impacts related to geopolitical developments in the Middle East and retailer inventory destocking. Against this backdrop, we are well-positioned to deliver on our 2026 outlook while building a foundation for long-term growth."First Quarter Results
As announced last quarter, the Company now reports results on both an All In and Core Perrigo basis. All In results reflect the entirety of our business, while Core represents our go-forward business and excludes Infant Formula and previously announced divestitures.
All In
Core
1Q'26
1Q'25
Change
1Q'26
1Q'25
ChangeReported Net Sales $969
$1,044
(7.2) %
$842
$918
(8.3) %Reported Gross Margin 33.6 %
37.6 %
(400)bps





Reported Operating Margin (38.4) %
4.5 %
n/m





Reported Diluted Earnings Per Share
("EPS")$(2.81)
$0.00
n/m


















All In
Core
1Q'26
1Q'25
Change
1Q'26
1Q'25
ChangeOrganic Net Sales(1) $939
$1,042
(9.9) %
$817
$918
(11.0) %Adj. Gross Margin 37.6 %
41.0 %
(340)bps
39.2 %
40.8 %
(160)bpsAdj. Operating Margin11.6 %
14.0 %
(240)bps
12.8 %
13.9 %
(110)bpsAdj. Diluted EPS$0.43
$0.60
(28.3) %
$0.40
$0.50
(20.0) %
(1) See attached Appendix for details. Change in net sales on an organic basis excludes the effects of acquisitions, divestitures and exited products, and the impact of currency. (2) Share gains according to Circana 13-weeks ending 03/29/26 vs. prior year period in the categories where Perrigo participates in cough cold, allergy, digestive health, pain, nicotine replacement, skin care, and women's health.(3) All tables and data may not add due to rounding. Percentages are based on actuals.Net SalesCore net sales were $842 million, declining 8.3% year over year, while Core organic net sales decreased 11.0%. Core organic results primarily reflect lower consumption across both the U.S. and Europe. Reduced consumption was driven in part by lower seasonal incidence of cough and cold versus the prior year, which was an approximately 3.5% net sales headwind, and also led to lower retailer inventory levels, creating an additional net sales headwind of approximately 3.0%. These factors were partially offset by continued market share gains, supported by innovation launches and performance of Women's Health products. Core organic net sales comprised net pricing of 0.2% and volume/mix of -11.0%.All In reported net sales declined 7.2% year over year to $969 million. The decrease was driven by the same factors impacting Core net sales, partially offset by Infant Formula net sales growth.Gross MarginReported gross margin was 33.6%, a decrease of 400 basis points versus the prior year due to the impact of prior-year manufacturing volume headwinds in Infant Formula and U.S. OTC, and lower net sales volumes, primarily within our Self Care reporting segment, partially offset by the net recognition of a recovery of a portion of previously paid tariffs of approximately $21 million.Core adjusted gross margin decreased 160 basis points to 39.2% driven by lower net sales volumes, the carryover impact of prior-year manufacturing volume headwinds in U.S. OTC, and unfavorable mix. These factors were partially offset by the net recognition of a recovery of a portion of previously paid tariffs and favorable currency translation.All In adjusted gross margin decreased 340 basis points to 37.6%, driven by the same factors impacting Core adjusted gross margin in addition to prior year manufacturing volume headwinds in Infant Formula.Operating MarginReported operating margin was (38.4)% compared to 4.5% in the prior-year due to the $330.8 million goodwill impairment charge.Core adjusted operating margin decreased 110 basis points to 12.8% primarily due to unfavorable gross margin. This decline was partially offset by reduced advertising and promotional expense, primarily from planned lower Opill® investment levels, benefits from the Operational Enhancement Program, and favorable currency translation.All In adjusted operating margin decreased 240 basis points to 11.6%, primarily driven by the same factors impacting Core adjusted operating margin in addition to the impact from Infant Formula.Other ItemsReported net interest and other expense decreased $2.4 million to $36.2 million due to the hedging of expected proceeds in Euro from the Dermacosmetics business sale.Net adjusted interest and other expense increased $5.0 million to $42.9 million due to lower interest income compared to prior year.The Company's reported effective tax rate was 4.6%. The Company's adjusted effective tax rate decreased 790 basis points to 15.5%, primarily due to the release of reserves for uncertain tax positions in 2026.Diluted EPSReported diluted EPS was $(2.81) due primarily to the $330.8 million goodwill impairment charge.Core adjusted EPS declined 10 cents to $0.40, a 20.0% decrease from the prior year.   All In adjusted diluted EPS declined 17 cents to $0.43, a 28.3% decrease from the prior year.Business Segment Results
1Q'26
1Q'25
Change
Organic
ChangeSegment net sales:






Self Care $543
$614
(11.5) %
(14.0) %Specialty Care 207
199
4.0 %
(0.8) %Infant Formula 90
88
2.1 %
1.9 %Total segment net sales840
901
(6.8) %
(9.5) %All Other 129
143
(9.5) %
(11.8) %Consolidated net sales$969
$1,044
(7.2) %
(9.9) % 
1Q'26
1Q'25
Change Segment operating income:




Self Care $68
$113
(39.3) %Specialty Care 55
42
31.4 %Infant Formula (7)
11
n/mTotal segment operating income$116
$165
(29.7) %All Other 32
21
52.1 %Unallocated(35)
(40)
(11.2) %Consolidated adjusted operating
income$113
$147
(23.0) %Self Care
Net sales decreased 11.5% compared to the prior year, inclusive of a 2.8% favorable impact of currency translation. The decline was driven by lower consumption in the U.S. and Europe, partly reflecting reduced seasonal incidence of cough and cold versus the prior year. This lower incidence pressured sales in the Upper Respiratory and Pain & Sleep categories, accounting for a significant portion of the segment's net sales decline. The remaining decline reflected softer consumption in the Digestive Health and Healthy Lifestyles categories. Reduced consumption also led to lower retail inventory levels across the segment. These factors were partially offset by continued market share gains in the U.S. and Europe. Notably, Perrigo U.S. store brand OTC volume share2 increased 100 basis points.Segment operating income decreased 39.3%, due primarily to the impact of prior-year manufacturing volume headwinds, lower net sales volumes, and unfavorable mix. These factors were partially offset by the net recognition of a recovery of a portion of previously paid tariffs in addition to favorable currency translation.Specialty Care
Net sales increased 4.0%, inclusive of a 4.8% favorable effect of currency translation, driven by growth in the Women's Health category, particularly continued momentum from Opill® and ellaOne®. This growth was partially offset by Skin Health results as lower store brand sales of Minoxidil at one customer were partially offset by share gains in Compeed® and Jungle Formula®.Segment operating income increased 31.4% as lower advertising and promotional spend, including planned lower Opill® investment levels, favorable currency translation, and the net recognition of a recovery of a portion of previously paid tariffs more than offset the impact of prior-year manufacturing volume headwinds and unfavorable mix.Infant Formula
Net sales increased 2.1%, inclusive of a 0.3% favorable effect of currency translation, driven by growth in contract infant formula. This growth was partially offset by lower net sales in store brand and branded infant formula due to tougher prior-year comparisons, including elevated sales from customer inventory replenishment.Segment operating income decreased primarily due to unfavorable gross profit flow through from prior-year manufacturing volume headwinds, partly offset by lower operating expenses.All Other
Net sales decreased 9.5%, inclusive of a 2.4% favorable effect of currency translation, driven in part by reduced distribution of lower-margin products.Segment operating income increased 52.1% due to the net recognition of a recovery of a portion of previously paid tariffs, favorable mix in the Oral Care category, and lower operating expenses.Cash Flow and Balance SheetFirst quarter 2026 cash for operating activities decreased $49 million to an outflow of $114 million due to lower earnings and higher working capital, in line with the Company's expected full-year cash flow phasing.First quarter capital expenditures were $14 million and the Company returned $40 million to shareholders through dividends.Cash and cash equivalents as of March 31, 2026, were $357 million while total debt was $3.6 billion.  After quarter end, the Company completed the sale of its Dermacosmetics business for total consideration of up to €332.6 million. The transaction consists of €305.6 million in upfront cash, including €5.6 million in net working capital adjustments, and up to an additional €27.0 million contingent on the achievement of net sales milestones over the next three years.Fiscal 2026 Outlook The Company reaffirms its 2026 outlook. Second-half results are expected to benefit from previously stated growth initiatives, the Operational Enhancement Program, and lapping of prior-year category consumption and manufacturing volume headwinds. As indicated last quarter, prior-year manufacturing volume headwinds are expected to result in an unfavorable All In EPS impact of approximately $0.60 in 2026. The Company experienced roughly $0.26 of that impact in the first quarter. The Company continues to closely monitor potential impacts from geopolitical developments in the Middle East. The Company is also monitoring retailer inventory levels and expects stabilization as consumption trends improve.
All In
Ex Infant
Formula
Ex Divestitures
Core
Foreign
Currency
Organic
CoreNet Sales Growth (5.5)% to (1.5)%
—
~270 bps
(3.0)% to +1.0%
(0.5) %
(3.5)% to +0.5%Adj. Gross Margin 36.5% to 37.5%
~240 bps
~(10) bps
39.0% to 40.0%



Adj. Operating Margin12.5% to 13.5%
~260 bps
~(10) bps
15.0% to 16.0%



Adj. EPS$2.00 to $2.30
~$0.30
~$(0.05)
$2.25 to $2.55



Other assumptionsNet interest expense of approximately $156 million.Adjusted effective tax rate of approximately 20.0%.Adjusted weighted average shares outstanding of approximately 140.5 million.Net leverage of, or slightly lower than, approximately 4.0 times adjusted EBITDA.Cash from operating activities as a percentage of adjusted net income in the mid-60% range.Webcast and Conference Call Information Perrigo previously announced that management will host a call/webcast to discuss its first quarter 2026 financial results beginning at 08:30 A.M. (EST) Wednesday, May 6, 2026. The call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 82404. A taped replay of the call will be available beginning at approximately 12:00 P.M. (EST) Wednesday, May 6, until midnight Wednesday, May 13, 2026. To listen to the replay, dial 888-660-6345, International 646-517-4150, and use access code 82404#.About PerrigoPerrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.For more information, visit www.perrigo.com. Forward-Looking StatementsCertain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this report, including certain statements contained in "Management's Discussion and Analysis of Financial Condition and Results of Operations" are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "forecast," "predict," "potential" or the negative of those terms or other comparable terminology. We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control, including: our ability to complete the proposed divestment of the Dermacosmetics branded business, receipt of works council and regulatory approval regarding the transaction, performance by counterparties to the transaction and the likelihood of satisfying the deferred payment milestones associated with the transaction, supply chain impacts on our business, including those caused or exacerbated by armed conflict, trade and other economic sanctions and/or disease; general economic, credit, and market conditions; increased or new tariffs by the U.S. or foreign governments (and any retaliatory or reciprocal tariffs) and changes in global trade relations; the impact of the war in Ukraine and any escalation thereof, including the effects of economic and political sanctions imposed by the United States, United Kingdom, European Union, and other countries related thereto; the outbreak or escalation of conflict in other regions where we do business, including the ongoing conflict and social, political and economic environment in Israel and the broader Middle East; current and future impairment charges, if we determine that the carrying amount of specific assets may not be recoverable from the expected future cash flows of such assets; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than we do; pricing pressures from customers and consumers; resolution of uncertain tax positions and any litigation relating thereto, ongoing or future government investigations and regulatory initiatives; uncertainty regarding our ability to obtain and maintain our regulatory approvals; potential costs and reputational impact of product recalls or sales halts; potential adverse changes to U.S. and foreign tax, healthcare and other government policy; the effect of epidemic or pandemic disease; the timing, amount and cost of any share repurchases (or the absence thereof) and/or any refinancing of outstanding debt at or prior to maturity; fluctuations in currency exchange rates and interest rates; receipt of potential earnout payments in connection with the sale of the HRA Rare Diseases Business and the risk that potential costs or liabilities incurred or retained in connection with this transaction may exceed our estimates or adversely affect our business or operations; the risk that potential costs or liabilities incurred or retained in connection with the sale of our Rx business may exceed our estimates or adversely affect our business or operations; the consummation and success of other announced and unannounced acquisitions or dispositions, and our ability to realize the desired benefits thereof; and our ability to execute and achieve the desired benefits of announced cost-reduction efforts and other strategic initiatives and investments, including our ability to achieve the expected benefits from our ongoing restructuring programs and strategic review processes described herein. Adverse results with respect to pending litigation could have a material adverse impact on our operating results, cash flows and liquidity, and could ultimately require the use of corporate assets to pay damages, reducing assets that would otherwise be available for other corporate purposes. These and other important factors, including those discussed in our Form 10-K for the year ended December 31, 2025, and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.Non-GAAP MeasuresThis press release contains certain non-GAAP measures. A "non-GAAP financial measure" is defined as a numerical measure of a company's financial performance that excludes or includes amounts different from the most directly comparable measure calculated and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP) in the statements of operations, balance sheets or statements of cash flows of the Company. Pursuant to the requirements of the U.S. Securities and Exchange Commission, the Company has provided reconciliations to the most directly comparable U.S. GAAP measures for the following 'All In' and 'Core' non-GAAP financial measures referred to in this press release:net sales growth on an organic basis, which excludes acquisitions, divestitures and exited products, and the impact of currency, adjusted gross profit, adjusted gross margin,adjusted operating income,adjusted operating margin,adjusted net income, adjusted diluted earnings per share,These non-GAAP financial measures should be considered as supplements to the GAAP reported measures, should not be considered replacements for, or superior to the GAAP measures and may not be comparable to similarly named measures used by other companies. The Company presents these non-GAAP financial measures in order to provide transparency to our investors because they are measures that management uses to assess both management performance and the financial performance of our operations and to allocate resources. In addition, management believes that these measures may assist investors with understanding and evaluating our initiatives to drive improved financial performance and enables investors to supplementally compare our operating performance with the operating performance of our competitors including with those of our competitors having different capital structures. While we have excluded certain of these items from historical non-GAAP financial measures, there is no guarantee that the items excluded from non-GAAP financial measures will not continue into future periods.?For instance, we expect to continue to experience and report restructuring-related charges associated with continued execution of our strategic initiatives.The Company provides non-GAAP financial measures as additional information that it believes is useful to investors and analysts in evaluating the performance of the Company's ongoing operating trends, facilitating comparability between periods and, where applicable, with companies in similar industries and assessing the Company's prospects for future performance. These non-GAAP financial measures exclude items, such as amortization expense, unusual litigation, impairment charges, restructuring charges, and acquisition and integration-related charges, that by their nature affect comparability of operational performance or that we believe obscure underlying business operational trends. The intangible asset amortization excluded from these non-GAAP financial measures represents the entire amount recorded within the Company's GAAP financial statements and is excluded because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised. The revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. The non-GAAP measures the Company provides are consistent with how management analyzes and assesses the operating performance of the Company, and disclosing them provides investor insight into management's view of the business. Management uses these adjusted financial measures for planning and forecasting in future periods, and evaluating segment and overall operating performance. In addition, management uses certain of the profit measures as factors in determining compensation.Non-GAAP measures related to profit measurements, which may include adjusted gross profit, adjusted net income, adjusted operating income, adjusted diluted earnings per share, adjusted gross margin, constant currency net sales, and adjusted operating margin are useful to investors as they provide them with supplemental information to enhance their understanding of the Company's underlying business performance and trends, and enhance the ability of investors and analysts to compare the Company's period-to-period financial results. Management believes that adjusted gross margin and adjusted operating margin are useful to investors, in addition to the reasons discussed above, by allowing them to more easily compare and analyze trends in the Company's peer business group and assisting them in comparing the Company's overall performance to that of its competitors. The Company also discloses net sales growth excluding the impact of currency on an organic basis. In addition, the Company presents non-GAAP measures for 'Core' Perrigo, reflecting its go-forward business and excluding infant formula currently under strategic review and previously announced divestitures. Core measures may include Core net income, Core net sales, Core organic net sales, Core gross profit, Core operating income, Core diluted earnings per share, Core gross margin, and Core operating margin, including on an organic, constant-currency basis. Management believes these measures provide greater consistency in financial reporting and facilitate meaningful comparisons of underlying operating results and acquisition and divestiture activity.The Company cannot reconcile its 'All In' or 'Core' expected organic net sales growth, adjusted gross margin, adjusted operating margin, adjusted earnings per share, adjusted diluted earnings per share, or adjusted effective tax rate to the most directly comparable GAAP measures under "Fiscal Year 2026 Outlook from Continuing Operations" without unreasonable effort because certain items that impact net income and other reconciling metrics are out of the Company's control and/or cannot be reasonably predicted at this time. These items include, but are not limited to, uncertainty of non-recurring infant formula related charges and timing and amount of restructuring charges and the income tax effects of these items or other income tax-related events.The Company believes these supplemental financial measures provide investors with consistency in financial reporting, enabling meaningful comparisons of past and present underlying operating results, and also facilitate analysis of the Company's operating performance and acquisition and divestiture trends.A copy of this press release, including the reconciliations, is available on the Company's website at www.perrigo.com. Perrigo ContactsEric Jacobson, Vice President, Global Investor Relations
(616) 886-0375, eric.jacobson@perrigo.com Nick Gallagher, Associate Director, Global Investor Relations
(269) 686-3238, nicholas.gallagher@perrigo.com PERRIGO COMPANY PLCCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in millions, except per share amounts)(unaudited)

Three Months Ended
March 28, 2026
March 29, 2025Net sales$               969.2
$           1,043.9Cost of sales643.7
651.6Gross profit325.5
392.3



Operating expenses


Distribution22.6
22.8Research and development24.6
26.7Selling129.7
146.2Administration115.0
112.2Impairment charges330.8
3.1Restructuring75.1
29.4Other operating expense, net—
5.0  Total operating expenses697.8
345.4



Operating income (loss)(372.3)
46.9



Interest expense, net40.8
39.0Other (income), net(6.0)
(0.4)Loss on extinguishment of debt1.4
—Income (loss) from continuing operations before
income taxes(408.5)
8.3Income tax expense (benefit)(18.7)
8.2Income (loss) from continuing operations(389.8)
0.1Loss from discontinued operations, net of tax(8.7)
(6.5)Net income (loss)$             (398.6)
$                 (6.4)



Earnings (loss) per share


Basic


Continuing operations$               (2.81)
$                0.00Discontinued operations(0.06)
(0.05)  Basic earnings (loss) per share$               (2.87)
$               (0.05)Diluted


Continuing operations$               (2.81)
$                0.00Discontinued operations(0.06)
(0.05)  Diluted earnings (loss) per share$               (2.87)
$               (0.05)



Weighted-average shares outstanding


Basic138.7
137.7Diluted138.7
137.7 PERRIGO COMPANY PLCCONDENSED CONSOLIDATED BALANCE SHEETS(in millions, except per share amounts)(unaudited)

March 28, 2026
December 31,
2025Assets


Cash and cash equivalents$                 357.2
$                531.6Accounts receivable, net of allowance for credit losses of $4.3 and $6.5,
respectively697.1
612.8Inventories1,121.4
1,149.0Prepaid expenses and other current assets272.2
231.4Current assets held for sale264.6
272.6Total current assets2,712.4
2,797.4Property, plant and equipment, net877.7
898.7Operating lease assets162.3
167.8Goodwill and indefinite-lived intangible assets1,706.4
2,054.7Definite-lived intangible assets, net2,259.3
2,351.5Deferred income taxes4.7
3.3Other non-current assets260.5
261.8Total non-current assets5,270.9
5,737.8Total assets$              7,983.3
$             8,535.2Liabilities and Shareholders' Equity


Liabilities


Accounts payable$                 434.8
$                474.5Payroll and related taxes153.5
112.2Accrued customer programs105.7
111.4Other accrued liabilities234.7
230.6Accrued income taxes28.6
20.8Current indebtedness11.4
36.6Current liabilities held for sale28.9
26.8Total current liabilities997.6
1,012.9Non-current liabilities


Long-term debt, less current portion3,621.1
3,603.6Deferred income taxes153.5
168.9Other non-current liabilities712.3
814.3Total non-current liabilities4,486.9
4,586.8Total liabilities5,484.5
5,599.7Contingencies - Refer to Note 16


Shareholders' equity


Controlling interests:


  Preferred shares, $0.0001 par value per share, 10 shares authorized—
—  Ordinary shares, €0.001 par value per share, 10,000 shares authorized6,578.1
6,608.2  Accumulated other comprehensive income (loss)(3.0)
4.8  Retained earnings (accumulated deficit)(4,076.3)
(3,677.5)  Total shareholders' equity2,498.8
2,935.5  Total liabilities and shareholders' equity$              7,983.3
$             8,535.2



Supplemental Disclosures of Balance Sheet Information


Preferred shares, issued and outstanding—
—Ordinary shares, issued and outstanding138.1
137.6 PERRIGO COMPANY PLCCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in millions)(unaudited)

Three Months Ended
March 28, 2026
March 29, 2025Cash Flows From (For) Operating Activities


Net income (loss)$               (398.6)
$                  (6.4)Adjustments to derive cash flows:


  Depreciation and amortization83.3
79.9  Restructuring charges71.4
29.4  Share-based compensation14.4
11.6  Impairment charges330.8
3.1  Amortization of debt discount2.2
2.2  Deferred income taxes(12.9)
(3.1)  Amortization on hedging instruments(4.9)
(6.4)  Other non-cash adjustments, net(3.2)
4.6  Subtotal82.7
114.9Increase (decrease) in cash due to:


  Inventories23.6
(62.5)  Accrued income taxes(13.2)
3.6  Payroll and related taxes(24.9)
(18.4)  Accounts payable(35.9)
7.2  Accrued customer programs(2.5)
6.4  Other accrued liabilities (7.7)
(56.1)  Accounts receivable(92.5)
(65.2)  Other long term liabilities2.7
(0.5)  Prepaid expenses and other current assets(45.9)
6.1  Subtotal(196.3)
(179.4)  Net cash for operating activities(113.6)
(64.5)Cash Flows From (For) Investing Activities


Proceeds from royalty rights1.4
1.7Asset acquisitions, net—
(1.5)Additions to property, plant and equipment(13.8)
(25.5)Other investing, net—
(0.4)Net cash for investing activities(12.4)
(25.7)Cash Flows From (For) Financing Activities


Payments on long-term debt(424.3)
(8.8)Cash dividends(39.9)
(40.6)Borrowings of revolving credit agreements and other financing, net427.6
—Payments for debt issuance costs(5.5)
—Shares used to settle taxes(2.8)
(11.9)Other financing, net(0.5)
(0.5)Net cash for financing activities(45.3)
(61.8)Effect of exchange rate changes on cash and cash equivalents(3.1)
10.3Net decrease in cash and cash equivalents(174.4)
(141.7)Cash and cash equivalents of continuing operations, beginning of period531.6
558.8Cash and cash equivalents held for sale, beginning of period2.3
—Less cash and cash equivalents held for sale, end of period(2.3)
(7.2)Cash and cash equivalents of continuing operations, end of period$                357.2
$                409.9 TABLE IPERRIGO COMPANY PLCRECONCILIATION OF NON-GAAP MEASURESSELECTED CONSOLIDATED INFORMATION(in millions, except per share amounts)(unaudited)

Three Months Ended March 28, 2026
Three Months Ended March 29, 2025Consolidated Continuing
OperationsGross
Profit Operating
Income
(Loss)Income
(Loss)
from
Continuing
OperationsDiluted
Earnings
(Loss) per
Share
Gross
Profit Operating
IncomeIncome
from
Continuing
OperationsDiluted
Earnings
per ShareReported$       325.5$      (372.3)$       (389.8)$           (2.81)
$       392.3$         46.9$            0.1$            0.00As a % of reported net sales(1) 33.6 %(38.4) %(40.2) %

37.6 %4.5 %— %
Pre-tax adjustments(2):








Amortization expense related
primarily to acquired intangible
assets35.454.554.50.39
34.555.055.60.40Impairment charges(3)—330.8330.82.39
—3.13.10.02Unusual litigation —16.616.60.12
—8.98.90.06Restructuring charges and other
termination benefits—75.175.10.54
—29.429.40.21Infant formula remediation ————
0.90.90.90.01Loss on divestitures————
——0.2—Loss on debt extinguishment ——1.40.01
————Other(4)3.48.20.2—
—2.42.40.02Non-GAAP tax adjustments(5)——(29.6)(0.21)
——(17.3)(0.12)Adjusted$       364.3$       112.8$          59.1$            0.43
$       427.7$       146.6$          83.2$            0.60As a % of reported net sales(1) 37.6 %11.6 %6.1 %

41.0 %14.0 %8.0 %










Diluted weighted average shares outstanding (in millions)








 Reported 138.7



137.7   Effect of dilution as reported amount was a loss, while adjusted amount
was income(6)0.3



0.9


 Adjusted 139.0



138.6
Note: Amounts may not add or recalculate due to rounding. Percentages are based on actuals.
(1)Reported net sales for the three months ended March 28, 2026 and March 29, 2025 were $969.2 million and $1,043.9 million, respectively.(2)Individual pre-tax line item adjustments have not been tax effected, as tax expense on these items are aggregated in the "Non-GAAP tax adjustments" line item.(3)During the three months ended March 28, 2026, we determined the carrying value of our reporting units exceeded their estimated fair value and recorded a goodwill impairment charge of  $330.8 million. During the three months ended March 29, 2025, we determined the carrying value of the Richard Bittner Business net assets held for sale exceeded their fair value less costs to sell, resulting in a total impairment charge of $3.1 million, inclusive of a goodwill impairment charge of $1.2 million.(4)Other pre-tax adjustments impacting reported income from continuing operations for the three months ended March 28, 2026 includes $4.7 million of professional consulting fees for potential divestiture activity more than offset by $8.0 million of favorable hedging activity related to potential divestiture activity and $3.5 million of accelerated depreciation. Other pre-tax adjustments for the three months ended March 29, 2025 are related to professional consulting fees for potential divestiture activity.(5)Non-GAAP tax adjustments for the three months ended March 28, 2026 are primarily due to (1) removal of $22.9 million of tax benefit on pre-tax non-GAAP adjustments and (2) removal of $7.3 million of tax benefits related to the release of uncertain tax positions. Non-GAAP tax adjustments for the three months ended March 29, 2025 are primarily due to $19.6 million of tax expense on pre-tax non-GAAP adjustments.(6)In the period of a net loss, reported diluted shares outstanding equal basic shares outstanding. TABLE IIPERRIGO COMPANY PLCRECONCILIATION OF NON-GAAP MEASURESSELECTED CONSOLIDATED INFORMATION(in millions, except per share amounts)(unaudited)

Three Months Ended March 28, 2026
Three Months Ended March 29, 2025Consolidated Continuing
OperationsR&D
ExpenseDSG&A
ExpenseRestructuring,
Impairments and
Other
R&D
Expense DSG&A
ExpenseRestructuring,
Impairments and
OtherReported$         24.6$       267.3$       405.9
$         26.7$       281.2$         37.5As a % of reported net sales(1) 2.5 %27.6 %41.9 %
2.6 %26.9 %3.6 %Pre-tax adjustments(2):






Amortization expense related
primarily to acquired intangible
assets(0.2)(18.9)—
(0.2)(20.3)—Impairment charges(3)——(330.8)
——(3.1)Restructuring charges and other
termination benefits——(75.1)
——(29.4)Unusual litigation —(16.6)—
—(3.8)(5.1)Other(4)(0.1)(4.7)—
—(2.4)—Adjusted$         24.3$       227.2$           —
$         26.5$       254.6$           —As a % of reported net sales(1) 2.5 %23.4 %— %
2.5 %24.4 %— %
Note: Amounts may not add or recalculate due to rounding. Percentages are based on actuals.
(1)Reported net sales for the three months ended March 28, 2026 and March 29, 2025 were $969.2 million and $1,043.9 million, respectively.(2)Individual pre-tax line item adjustments have not been tax effected, as tax expense on these items are aggregated in the "Non-GAAP tax adjustments" line item.(3)During the three months ended March 28, 2026, we determined the carrying value of our reporting units exceeded their estimated fair value and recorded a goodwill impairment charge of $330.8 million. During the three months ended March 29, 2025, we determined the carrying value of the Richard Bittner Business net assets held for sale exceeded their fair value less costs to sell, resulting in a total impairment charge of $3.1 million, inclusive of a goodwill impairment charge of $1.2 million.(4)Other pre-tax adjustments for the three months ended March 28, 2026 includes $4.7 million of professional consulting fees for potential divestiture activity. Other pre-tax adjustments for the three months ended March 29, 2025 are related to professional consulting fees for potential divestiture activity. TABLE IIIPERRIGO COMPANY PLCRECONCILIATION OF NON-GAAP MEASURESSELECTED CONSOLIDATED INFORMATION(in millions, except per share amounts)(unaudited)

Three Months Ended March 28, 2026
Three Months Ended March 29, 2025Consolidated Continuing
OperationsInterest and
OtherIncome Tax
Expense (Benefit)
Interest and
Other Income Tax
ExpenseReported$                36.2$               (18.7)
$               38.6$                8.2As a % of reported net sales(1) 3.7 %(1.9) %
3.7 %0.8 %Effective tax rate
4.6 %

99.0 %Pre-tax adjustments(2):




Amortization expense related
primarily to acquired intangible
assets——
(0.5)—Loss on divestitures——
(0.2)—Loss on debt extinguishment (1.4)—
——Other(3)8.0—
——Non-GAAP tax adjustments(4)—29.6
—17.3Adjusted$                42.9$                10.8
$               37.9$               25.5As a % of reported net sales(1) 4.4 %1.1 %
3.6 %2.4 %Adjusted effective tax rate
15.5 %

23.4 %
Note: Amounts may not add or recalculate due to rounding. Percentages are based on actuals.
(1)Reported net sales for the three months ended March 28, 2026 and March 29, 2025 were $969.2 million and $1,043.9 million, respectively.(2)Individual pre-tax line item adjustments have not been tax effected, as tax expense on these items are aggregated in the "Non-GAAP tax adjustments" line item.(3)Other pre-tax adjustments impacting reported interest and other from continuing operations for the three months ended March 28, 2026 includes $8.0 million of favorable hedging activity related to potential divestiture activity.(4)Non-GAAP tax adjustments for the three months ended March 28, 2026 are primarily due to (1) removal of $22.9 million of tax benefit on pre-tax non-GAAP adjustments and (2) removal of $7.3 million of tax benefits related to the release of uncertain tax positions. Non-GAAP tax adjustments for the three months ended March 29, 2025 are primarily due to $19.6 million of tax expense on pre-tax non-GAAP adjustments. TABLE IVPERRIGO COMPANY PLCRECONCILIATION OF NON-GAAP MEASURESSELECTED CONSOLIDATED INFORMATION(in millions, except per share amounts)(unaudited)

Three Months Ended

Consolidated Continuing OperationsMarch 28, 2026
March 29, 2025
% ChangeNet Sales $          969.2
$        1,043.9
(7.2) %Less: Currency impact(1)30.1
—
2.9 %Constant currency net sales $          939.2
$        1,043.9
(10.0) %Less: Divestitures and exited products(2)0.1
2.0
0.1 %Organic net sales $          939.1
$        1,041.9
(9.9) %
Self Care




Net Sales $          543.3
$          614.3
(11.5) %Less: Currency impact(1)16.9
—
2.8 %Constant currency net sales $          526.4
$          614.3
(14.3) %Less: Divestitures and exited products(2)0.1
2.0
0.3 %Organic net sales $          526.4
$          612.3
(14.0) %
Specialty Care




Net Sales $          207.0
$          199.1
4.0 %Less: Currency impact(1)9.5
—
4.8 %Organic net sales $          197.5
$          199.1
(0.8) %
Infant Formula




Net Sales $            89.7
$            87.8
2.1 %Less: Currency impact(1)0.2
—
0.3 %Organic net sales $            89.5
$            87.8
1.9 %
All Other




Net Sales$          129.2
$          142.7
(9.5) %Less: Currency impact(1)3.4
—
2.4 %Organic net sales $          125.8
$          142.7
(11.8) %

Note: Amounts may not add or recalculate due to rounding. Percentages are based on actuals.

(1)Currency impact is calculated using the exchange rates used to translate our financial statements in the comparable prior year period to show what current period US dollar results would have been if such currency exchange rates had not changed.(2)Represents divestiture of the Richard Bittner Business and exited products within the Self Care segment. TABLE VPERRIGO COMPANY PLCRECONCILIATION OF NON-GAAP MEASURESSELECTED CONSOLIDATED INFORMATION(in millions, except per share amounts)(unaudited)

Three Months Ended March 28, 2026
Three Months Ended March 29, 2025Consolidated Continuing
OperationsNet
SalesGross
Profit Operating
IncomeIncome
from
Continuing
OperationsDiluted
Earnings
per
Share
Net
Sales Gross
Profit Operating
IncomeIncome
from
Continuing
OperationsDiluted
Earnings
per
ShareAll In Adjusted $    969.2$  364.3$   112.8$       59.1$       0.43
$  1,043.9$  427.7$   146.6$       83.2$       0.60As a % of reported net sales
37.6 %11.6 %6.1 %


41.0 %14.0 %8.0 %
Core Adjustments:










Less: Prior Year
Divestitures(1)0.10.10.10.1—
2.01.40.80.80.01Less: Infant Formula89.710.6(7.4)(7.4)(0.05)
87.832.610.610.60.08Less: Previously Announced
Divestitures(2)37.723.712.312.30.09
36.519.07.57.50.05Non-GAAP tax adjustments———(0.8)0.01
———(4.5)(0.03)Core Adjusted$    841.8$  329.8$   107.9$       54.9$       0.40
$     917.6$  374.6$   127.7$       68.7$       0.50As a % of Core net sales
39.2 %12.8 %5.7 %


40.8 %13.9 %7.5 %
Less: Currency impact(3)25.3









Core Organic $    816.5





















Diluted weighted average shares outstanding (in millions)










 Reported
138.7




137.7Effect of dilution as reported amount was a loss, while
adjusted amount was income(4)
0.3




0.9


 Adjusted
139.0




138.6
Note: Amounts may not add or recalculate due to rounding. Percentages are based on actuals.
(1)Represents divestiture of the Richard Bittner Business and exited products within the Self Care segment.(2)Represents previously announced divestitures, primarily Dermacosmetics, and exited products.(3)Currency impact is calculated using the exchange rates used to translate our financial statements in the comparable prior year period to show what current period U.S. dollar results would have been if such currency exchange rates had not changed.(4)In the period of a net loss, reported diluted shares outstanding equal basic shares outstanding.  View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-reports-first-quarter-2026-financial-results-from-continuing-operations-302763932.htmlSOURCE Perrigo Company plc Original: Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations

Perrigo Completes Divestiture of Dermacosmetics BusinessApril 30, 2026 4:30 PM
PR Newswire (US)

Advances key Three-S plan pillar, streamlining portfolioUpfront net proceeds of approximately €306 million will enable debt reductionDUBLIN, April 30, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading global provider of consumer health products, today announced that it has completed the previously announced sale of its branded Dermacosmetics business to Karo Healthcare ("Karo") for total consideration of up to €332.6 million. The transaction consists of €305.6 million in upfront cash, including €5.6 million in net working capital adjustments, and up to an additional €27.0 million contingent on the achievement of net sales milestones over the next three years. Brands sold in the transaction include ACO, Biodermal, Emolium, and Iwostin.







"This transaction marks another important milestone in the execution of our Three-S plan to Stabilize, Streamline, and Strengthen the Company," said Patrick Lockwood-Taylor, President and Chief Executive Officer. "By further streamlining our portfolio and sharpening our focus on core categories, we are better positioned to leverage our competitive advantages and deliver more consistent and sustainable growth in shareholder value. Importantly, we expect the net proceeds from this transaction will be used primarily to reduce debt, enhancing our financial flexibility and strengthening our balance sheet."In calendar year 2025, Perrigo's Dermacosmetics branded business generated approximately €120 million in net sales and represented approximately 5% of Perrigo's adjusted operating income.AdvisorsGreenhill & Co., an affiliate of Mizuho, is serving as financial advisor to Perrigo, and Latham & Watkins is serving as legal advisor.About PerrigoPerrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers trusted self-care solutions that can be used without the need for a prescription, ensuring accessibility and choice for consumers across molecules, dosage forms, and value tiers.Perrigo's unique business model leverages its complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.For more information, visit www.perrigo.com. Non-GAAP MeasuresThis press release contains certain non-GAAP measures. A "non-GAAP financial measure" is defined as a numerical measure of a company's financial performance that excludes or includes amounts different from the most directly comparable measure calculated and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP) in the statements of operations, balance sheets or statements of cash flows of the Company. Pursuant to the requirements of the U.S. Securities and Exchange Commission, the Company has provided reconciliations to the most directly comparable U.S. GAAP measures for the non-GAAP financial measures referred to in this press release.These non-GAAP financial measures should be considered as supplements to the GAAP reported measures, should not be considered replacements for, or superior to the GAAP measures and may not be comparable to similarly named measures used by other companies.Perrigo Forward-Looking StatementsCertain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "forecast," "predict," "potential" or the negative of those terms or other comparable terminology.We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control, including the Company's ability to realize the anticipated benefits of the divestiture, including the expected impact on its portfolio focus, financial flexibility, debt reduction, and balance sheet; the timing, amount and certainty of receipt of any contingent consideration under the transaction, which is subject to the future net sales performance of the disposed business; the actual use of net proceeds from the transaction; the effects of macroeconomic conditions, foreign currency exchange rates and tax matters related to the transaction; and general market, economic, competitive and operational conditions. These and other important factors, including those discussed in our Form 10-K for the year ended December 31, 2025 and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.Perrigo ContactsEric Jacobson, Vice President, Global Investor Relations
eric.jacobson@perrigo.com Nick Gallagher, Associate Director, Global Investor Relations
nicholas.gallagher@perrigo.com TABLE I PERRIGO COMPANY PLC RECONCILIATION OF NON-GAAP MEASURE (in millions) (unaudited) 
Twelve Months Ended
December 31, 2025Consolidated Continuing Operations Net 
Sales
Operating
Income



Reported $           4,253.1
$   (1,122.2)



As a % of reported net sales 

(26.4) %Pre-tax adjustments: 


Amortization expense related primarily to acquired intangible assets 

223.5Restructuring charges and other termination benefits 

71.9Unusual litigation 

59.0Impairment charges(1) 

1,363.1Infant formula remediation 

0.9Other(2) 

26.1Adjusted Operating Income 

$        622.3As a % of reported net sales 

14.6 %



Adjusted Operating Income in Euros(3) 

€        551.4

(1)During the twelve months ended December 31, 2025 impairment charges were due primarily to a total goodwill impairment of $1.3 billion and the existence of an other-than-temporary impairment of our equity method investment in Kazmira LLC and recorded an impairment charge of $33.6 million.(2)Other pre-tax adjustments for the twelve months ended December 31, 2025 are partly due to $12.2 million of professional  consulting fees for potential divestiture activity.(3)Adjusted Operating Income was translated at the average exchange rate for the 2025 calendar year of 0.8860 EUR per USD. 



View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-completes-divestiture-of-dermacosmetics-business-302759218.htmlSOURCE Perrigo Company plc

Original: Perrigo Completes Divestiture of Dermacosmetics Business

Perrigo Announces Quarterly DividendApril 29, 2026 8:56 AM
PR Newswire (US)

DUBLIN, April 29, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of consumer products, today announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, or $1.16 per share on an annualized basis. The cash dividend is payable on June 16, 2026, to shareholders of record on May 29, 2026.







About Perrigo Perrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers trusted self-care solutions that can be used without the need for a prescription, ensuring accessibility and choice for consumers across molecules, dosage forms, and value tiers.Perrigo's unique business model leverages its complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.For more information, visit www.perrigo.com.Forward-Looking StatementsThis press release includes, and the matters discussed in Perrigo's upcoming earnings release will include certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements involve known and unknown risks, uncertainties and other factors—many of which are beyond the Company's control—that may cause the actual results, performance or achievements of the Company to be materially different from its current expectations, assumptions, estimates and projections. Interested persons are urged to consult the Company's filings with the United States Securities and Exchange Commission, available at https://investor.perrigo.com/sec-filings, for a discussion of the Company's business and financial condition and certain material trends, risks, uncertainties and other factors relating thereto, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2025.Perrigo ContactsEric Jacobson, Vice President, Global Investor Relations
eric.jacobson@perrigo.comNick Gallagher, Associate Director, Global Investor Relations
nicholas.gallagher@perrigo.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-announces-quarterly-dividend-302757261.htmlSOURCE Perrigo Company

Original: Perrigo Announces Quarterly Dividend

Perrigo to Release First Quarter 2026 Financial Results on May 6, 2026April 22, 2026 8:30 AM
PR Newswire (US)

DUBLIN, April 22, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer health products, today announced that it plans to issue its first quarter 2026 financial results on Wednesday, May 6, 2026, and host a conference call beginning at 8:30 A.M. (EST).







The earnings conference call will be available live via webcast in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 82404. A taped replay of the call will be available beginning at approximately 12:00 P.M. (EST) Wednesday, May 6, until midnight Wednesday, May 13, 2026. To listen to the replay, dial 888-660-6345, International 646-517-4150, and use access code 82404#.About PerrigoPerrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers trusted self-care solutions that can be used without the need for a prescription, ensuring accessibility and choice for consumers across molecules, dosage forms, and value tiers.Perrigo's unique business model leverages its complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.For more information, visit www.perrigo.com.Forward-Looking StatementsThis press release includes, and the matters discussed in Perrigo's upcoming earnings release will include certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements involve known and unknown risks, uncertainties and other factors—many of which are beyond the Company's control—that may cause the actual results, performance or achievements of the Company to be materially different from its current expectations, assumptions, estimates and projections. Interested persons are urged to consult the Company's filings with the United States Securities and Exchange Commission, available at https://investor.perrigo.com/sec-filings, for a discussion of the Company's business and financial condition and certain material trends, risks, uncertainties and other factors relating thereto, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2025.Perrigo ContactEric Jacobson, Vice President, Global Investor Relations
(616) 886-0375, eric.jacobson@perrigo.comNick Gallagher, Associate Director, Global Investor Relations
(269) 686-3238, nicholas.gallagher@perrigo.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-to-release-first-quarter-2026-financial-results-on-may-6-2026-302749501.htmlSOURCE Perrigo Company plc

Original: Perrigo to Release First Quarter 2026 Financial Results on May 6, 2026

Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing OperationsFebruary 26, 2026 6:31 AM
PR Newswire (US)

Delivered FY2025 Adj. EPS at the Midpoint of Updated Outlook RangeAdvanced '3-S Plan' with Perrigo Store Brand OTC and Key Brands Gaining Share1,2 in 2025, Despite Soft Category ConsumptionLaunching New Operational Enhancement Program - Expected to Deliver Pre-Tax Annualized Savings of $80 million to $100 millionTransitioning to New Reporting Segments Beginning Q1 2026, Aligned to Commercial Operating ModelIssues FY2026 'All In' Outlook; Introduces FY2026 'CORE' Outlook, which Excludes Infant Formula and Previously Announced DivestituresFourth Quarter 2025 YoY Highlights:Net Sales: $1.11 billion, -2.5% year-over-year as favorable FX +2.3% was more than offset by organic net sales -4.5% and the impact of divestitures and exited products -0.4%.Organic Net Sales: Down due primarily to -2.9% from Infant Formula. The rest of the business was down -1.6%, half of which stemmed from lower OTC contract manufacturing and the other half from soft total OTC category consumption, which was partially offset by market share gains.Diluted EPS: Reported EPS: $(10.20), down from $(0.30) in the prior year, due primarily to a Goodwill Impairment charge (see "Goodwill Impairment" section below). Adjusted EPS: $0.77, down from $0.93. Includes a year-over-year headwind of -$0.13 from Infant Formula, partially offset by a $0.06 tailwind from FX.Fiscal Year 2025 YoY Highlights:Net Sales: $4.25 billion, -2.8% year-over-year as favorable currency translation of 1.1% was more than offset by -2.4% from organic net sales and -1.5% from divestitures and exited products.Organic Net Sales: Down due primarily to -0.9% from Infant Formula, -0.5% from OTC contract manufacturing, -0.5% from Oral Care, and -0.3% from the absence of the prior-year Opill® launch stocking benefit. Organic net sales across the rest of the business were roughly flat.Diluted EPS: Reported EPS: $(10.12), down from $(1.17) in the prior year period, due primarily to the Goodwill Impairment charge. Adjusted EPS: $2.75, up $0.18 or 7.0%, from $2.57, including a tailwind of $0.10 from FX and headwind of -$0.12 from divestitures and exited products.Operating Cash Flow YTD: $239 million, reflecting fourth quarter cash flow of $175 million. Cash and cash equivalents on the balance sheet as of December 31, 2025 were $532 million.Fiscal Year 2026 Outlook Highlights:Company issues its FY2026 'All In' total net sales outlook of -5.5% to -1.5%, versus the prior year. FY2026 'All In' adjusted diluted EPS range outlook is $2.00 to $2.30.Company issues its FY2026 outlook for 'CORE' Perrigo reflecting its go-forward business, which excludes Infant Formula currently under strategic review and previously announced divestitures. CORE reported net sales outlook of -3.0% to +1.0% with CORE organic net sales outlook of - 3.5% to +0.5%, versus the prior year. FY2026 CORE adjusted EPS outlook range is $2.25 to $2.55, compared to FY2025 CORE adjusted EPS of $2.52.See "Fiscal Year 2026 Outlook from Continuing Operations" section below for more information on this outlook and these non-GAAP measures.(1)  Share gains according to Circana 13-weeks and/or 52-weeks ending 12/28/25 vs. prior year period in the categories where Perrigo participates in cough cold, allergy, digestive health, pain, nicotine replacement, skin care and women's health.(2)  Consolidation of various data sources (IQVIA, IRI, Nielsen, Openhealth, Newline, HMR, reddata, Farmastat) latest data available, ending December 2025.(3)  See attached Appendix for details. Change in net sales on an organic basis excludes the effects of acquisitions, divestitures and exited products, and the impact of currency.(4)  All tables and data may not add due to rounding. Percentages are based on actuals.DUBLIN, Feb. 26, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of consumer health products, today announced financial results from continuing operations for the fourth quarter and fiscal year ended December 31, 2025. All comparisons are against the prior year fourth quarter and fiscal year, unless otherwise noted.







President and CEO Patrick Lockwood-Taylor commented, "Fiscal year 2025 was a pivotal year for Perrigo. Despite soft category consumption and a challenging Infant Formula end-market, we gained share across store brands and in key brands as our team executed with discipline. These results reinforce the strength of our consumer-preferred portfolio, deep retail partnerships and sharpened focus on everyday consumer health. Our 'Three–S plan' is delivering meaningful progress in stabilizing our business, streamlining our complexity and strengthening what is working, supported by cost savings program benefits and the implementation of our new commercial operating model.""Looking ahead, we are prioritizing resources and investments towards CORE Perrigo, our go-forward business, which excludes the Infant Formula business under strategic review, and previously announced divestitures. Our 2026 outlook reflects near-term headwinds, balanced by favorable mix in our base business, disciplined execution of our new operational enhancement program and targeted cost actions to align our structure with current market realities. We are confident that our disciplined approach is enabling us to navigate the transition year ahead and positions Perrigo to create long-term value for our shareholders," concluded Lockwood-Taylor.Refer to Tables I through VII at the end of this press release for a reconciliation of non-GAAP adjustments to the current year and prior year periods and additional non-GAAP information. The Company's reported results are included in the attached Condensed Consolidated Statements of Operations, Balance Sheets and Statements of Cash Flows.Concluding Project EnergizeProject Energize, a global investment and efficiency program launched during the first quarter of 2024, delivered gross annualized pre-tax savings of approximately $167 million as of the end of FY2025, towards the high-end of the Company's estimated range of $140 million to $170 million.Reinvestments of savings of $35 million over the same period are within the Company's estimated range of $30 million to $40 million. Restructuring charges incurred by the Company over the same period in connection with Project Energize were approximately $138 million. As the program has substantively finalized, the Company anticipates less than $10 million of costs to be incurred through FY2026.Concluding Supply Chain Reinvention ProgramThe Company initiated a Supply Chain Reinvention Program in 2022 to reduce structural costs, improve profitability and service levels to retail partners, and strengthen Perrigo's resiliency by streamlining and simplifying the Company's global supply chain. The program was successfully completed and achieved cumulative annual run-rate benefits of $157 million in the fourth quarter of 2025, in the range of estimated program benefits of $150 million to $200 million (not including related depreciation expense on capital investments). Total costs incurred over the same period including capital investments, restructuring expenses and implementation costs were $286 million, below the estimated range of $300 million to $350 million originally expected to be incurred by the end of fiscal year 2028, with the substantial portion of the costs incurred by the end of FY2025. As the program has completed, the Company anticipates less than $10 million of costs to be incurred through FY2026.Agreement to Divest Dermacosmetics BusinessOn July 14, 2025, the Company announced it signed an agreement to sell the Company's Dermacosmetics branded business for up to €327 million, including €300 million in upfront cash and up to an additional €27 million contingent on the achievement of net sales milestones over the next three years. The Company anticipates this transaction closing in the second quarter of 2026, subject to customary closing conditions.Goodwill ImpairmentDuring the three months ended December 31, 2025, the Company's reporting units had an indication of potential impairment due to a sustained decrease in share price, lower expected cash flows principally related to infant formula market dynamics and a change in near-term expectations of the broader self-care market. As such, the Company recognized a goodwill impairment of $1.3 billion as of December 31, 2025.The Company is also required to reallocate goodwill from its existing reporting units to the new reporting units (see 'New Reporting Segments Beginning First Quarter 2026' below for details). While the total estimated fair and carrying values are unchanged from December 31, 2025, the redistribution of goodwill across the Company's new reporting units may cause the Company to record additional non–cash goodwill impairment charges of up to $350 million in the first quarter of 2026.Perrigo Fourth Quarter 2025 Results from Continuing OperationsFourth Quarter 2025 Net Sales Change Compared to Prior Year(5)
Reported
Net Sales
GrowthForeign
Exchange
ImpactConstant
Currency Net
SalesDivestitures &
Exited
ProductsOrganic
Net Sales
GrowthCSCA(6.3) %— %(6.3) %— %(6.3) %CSCI4.7 %6.8 %(2.1) %(1.1) %(1.0) %Total Perrigo(2.5) %2.3 %(4.9) %(0.4) %(4.5) %Net sales of $1.11 billion decreased 2.5%, or $29 million, including favorable currency translation of 2.3% and divestitures and exited products of -0.4%. Organic net sales declined 4.5%, comprising net pricing of -0.6% and volume/mix of -3.9%, driven primarily by infant formula.Organic net sales were unfavorably impacted by approximately 2.9% from infant formula. Organic net sales from the rest of the business were down 1.6%, half of which stemmed from store brand OTC contract manufacturing. The other half was primarily due to soft OTC category consumption, including a later start to the U.S. and European cough cold seasons, which was partially offset by accelerating store brand dollar, unit and volume share gains and stable dollar share across key brands. Perrigo U.S. store brands gained volume share1 of 120 basis points.Reported gross profit of $362 million decreased $24 million, or 6.1%. Adjusted gross profit of $401 million decreased $23 million, or 5.4%, due primarily to lower gross profit in infant formula of $23 million. Supply Chain Reinvention benefits in addition to favorable currency translation of $16 million offset lower gross profit across the rest of the business due primarily to lower net sales volumes and $2 million from divestitures and exited products.Reported gross margin was 32.6%, a decrease of 130 basis points. Adjusted gross margin decreased 110 basis points to 36.1%, due primarily to the same factors as adjusted gross profit. The year-over-year impact from infant formula was an unfavorable 100 basis points.Reported operating loss was $1.29 billion as compared to income of $114 million in the prior year period, due primarily to the Goodwill Impairment charge discussed above. Adjusted operating income was lower by $27 million, or 13.8%, to $167 million due primarily to unfavorable gross profit flow through and $2 million from divestitures and exited products. These factors were partially offset by Project Energize structural cost savings and favorable currency translation of $9 million.Reported operating margin was -116.0%, due primarily to the Goodwill Impairment charge discussed above. Adjusted operating margin of 15.1% was 200 basis points lower due primarily to the same factors as adjusted operating income. The year-over-year impact from infant formula was an unfavorable 140 basis points.Reported net loss was $1.41 billion, or $(10.20) per share, compared to a reported net loss of $41 million, or ($0.30) per share, in the prior year period, due primarily to the Goodwill Impairment charge discussed above. Adjusted net income was $108 million, or $0.77 per share, compared to $129 million, or $0.93 per share, down $0.16. Fourth quarter 2025 adjusted EPS included unfavorable impacts of $0.13 from infant formula and $0.01 from divestitures and exited products, partially offset by favorable currency translation of $0.06.Fourth Quarter 2025 Business Segment Results from Continuing OperationsConsumer Self-Care Americas Segment (CSCA)Fourth Quarter 2025 Net Sales Change Compared to Prior Year(5)
ReportedForeignConstantDivestitures &Organic
Net SalesExchangeCurrency NetExitedNet Sales
GrowthImpactSalesProductsGrowthCSCA(6.3) %— %(6.3) %— %(6.3) %CSCA net sales of $697 million declined $47 million, or 6.3%.Net sales were unfavorably impacted by approximately 4.4% from infant formula. Net sales from the rest of CSCA were down 1.9% due primarily to lower net sales from OTC contract manufacturing of 1.3% and soft OTC category consumption, partially offset by accelerating store brand volume share gains of 0.6%.Reported gross profit of $187 million decreased $30 million, or 13.9%. Adjusted gross profit decreased $31 million, or 13.4%, to $199 million primarily due to lower gross profit from infant formula of $23 million and lower sales volumes across the rest of the business, partially offset by benefits from Supply Chain Reinvention and favorable currency translation.Reported gross margin of 26.8% decreased 230 basis points. Adjusted gross margin decreased 230 basis points to 28.5%, driven by the same factors as adjusted gross profit. The year-over-year impact from infant formula was an unfavorable 180 basis points.Reported operating loss was $873 million compared to income of $83 million in the prior year, due primarily to the Goodwill Impairment charge discussed above. Adjusted operating income decreased $29 million, or 20.1%, to $117 million primarily due to unfavorable impacts from infant formula of $21 million in addition to gross profit flow through from the rest of the business, partially offset by Project Energize structural cost savings.Reported operating margin was -125.2%, due primarily to the Goodwill Impairment charge discussed above. Adjusted operating margin decreased 290 basis points to 16.7%, driven by the same factors as adjusted operating income. The year-over-year impact from infant formula was an unfavorable 210 basis points.Consumer Self-Care International Segment (CSCI)Fourth Quarter 2025 Net Sales Change Compared to Prior Year(5)
ReportedForeignConstantDivestitures &Organic
Net SalesExchangeCurrency NetExitedNet Sales
GrowthImpactSalesProductsGrowthCSCI4.7 %6.8 %(2.1) %(1.1) %(1.0) %CSCI net sales of $413 million increased 4.7%, or $19 million as favorable currency of 6.8% more than offset organic net sales decline of 1.0% and the impact from divestitures and exited products of 1.1%.Organic net sales drivers included 1) share gains in key brands, including Compeed®, ellaOne® and Jungle Formula®, and 2) new products, including Nasalmer® and others in the Physiomer® franchise. These drivers were more than offset by 1) soft total OTC category consumption and a softer cough cold season in Europe compared to the prior year, 2) the VMS category, reflecting reduced strategic focus on nutraceutical products within the category, and 3) price investments to drive brand promotions.Reported gross profit of $176 million increased $6 million, or 3.8%. Adjusted gross profit of $203 million increased $8 million, or 4.2%, as new products, Supply Chain Reinvention benefits and favorable currency translation of $14 million more than offset lower sales volumes and price investments to drive brand promotions.Reported gross margin of 42.6% decreased 40 basis points. Adjusted gross margin declined 20 basis points to 49.1%, driven primarily by the same factors as adjusted gross profit.Reported operating loss was $365 million compared to income of $40 million, due primarily to the Goodwill Impairment charge discussed above. Adjusted operating income of $90 million increased $6 million, or 7.4%, due primarily to favorable currency translation of $7 million.Reported operating margin was -88.5%, due primarily to the Goodwill Impairment charge discussed above. Adjusted operating margin expanded 50 basis points to 21.7%, driven primarily by the same factors as adjusted operating income.Perrigo Fiscal Year 2025 Results from Continuing OperationsFiscal Year 2025 Net Sales Change Compared to Prior Year(5)
Reported
Net Sales
GrowthForeign
Exchange
ImpactConstant
Currency Net
SalesDivested
Businesses
and Product
LinesOrganic
Net Sales
GrowthCSCA(4.0) %— %(4.0) %— %(4.0) %CSCI(0.7) %3.0 %(3.7) %(4.0) %0.3 %Total Perrigo(2.8) %1.1 %(3.9) %(1.5) %(2.4) %Net sales of $4.25 billion decreased 2.8%, or $120 million, due primarily to a decline in organic net sales of 2.4% and divested businesses and exited product lines of 1.5%, partially offset by favorable currency translation of 1.1%. Organic net sales comprised net pricing of -0.5% and volume/mix of -1.9%, half of which stemmed from infant formula.Organic net sales were down due primarily to -0.9% from infant formula, -0.5% from store brand OTC contract manufacturing, -0.5% from Oral Care, and -0.3% from the absence of the prior-year Opill® launch stocking benefit. Organic net sales across the rest of the business were roughly flat as soft OTC category consumption was offset by new products in addition to store brand dollar, unit and volume share gains and dollar share gains across key brands. Perrigo U.S. store brands gained volume share1 of 60 basis points and Perrigo key brands gained dollar share2 of 10 basis points.Reported gross profit of $1.49 billion, decreased $48 million, or 3.1%. Adjusted gross profit of $1.65 billion decreased $50 million, or 2.9%, as Supply Chain Reinvention benefits, new products and favorable currency translation were more than offset by lower global OTC sales volumes, net impact of pricing actions, and $42 million from divestitures and exited products.Reported gross margin was 35.1%, a decrease of 20 basis points versus the prior year. Adjusted gross margin was 38.7%, a decrease of 10 basis points due primarily to the same factors as adjusted gross profit, including an unfavorable impact from divestitures and exited products of 40 basis points.Reported operating loss was $1.12 billion compared to operating income of $113 million in the prior year, due primarily to the Goodwill Impairment charge discussed above. Adjusted operating income increased $14 million, or 2.3%, to $622 million as benefits from Project Energize, lower variable employee expenses and favorable currency translation of $17 million more than offset lower gross profit flow through and $21 million from divestitures and exited products.Reported operating margin was -26.4%, due primarily to the Goodwill Impairment charge discussed above. Adjusted operating margin of 14.6%, expanded 70 basis points due primarily to the same factors as adjusted operating income, including an unfavorable impact from divestitures and exited products of 30 basis points.Reported net loss was $1.40 billion, or ($10.12) per share, compared to a net loss of $161 million, or ($1.17) per share, in the prior year, due primarily to the Goodwill Impairment charge discussed above. Fiscal year 2025 adjusted net income was $382 million, or $2.75 per share, compared to $354 million, or $2.57 per share in the prior year. Fiscal year 2025 adjusted EPS included a $(0.12) impact from divestitures and exited products, partially offset by $0.10 from favorable currency translation.Fiscal Year 2025 Business Segment Results from Continuing OperationsConsumer Self-Care Americas SegmentFiscal Year 2025 Net Sales Change Compared to Prior Year(5)
Reported
Net Sales
GrowthForeign
Exchange
ImpactConstant
Currency Net
SalesDivested
Businesses
and Product
LinesOrganic
Net Sales
GrowthCSCA(4.0) %— %(4.0) %— %(4.0) %CSCA net sales of $2.59 billion decreased 4.0%, or $108 million. Net sales were unfavorably impacted by 1.4% from infant formula, 0.7% from store brand OTC contract manufacturing, 0.7% from Oral Care and 0.6% from the absence of the prior-year Opill® launch stocking benefit. Net sales from the rest of the CSCA business were down 0.6% as net price investments to drive volume and soft OTC category consumption were partially offset by accelerating store brand volume share gains.Reported gross profit of $755 million, decreased $24 million, or 3.1%. Adjusted gross profit of $802 million decreased $27 million, or 3.2%, as benefits from Supply Chain Reinvention and actions to augment and strengthen infant formula were more than offset by lower sales volumes and net price investments to drive volume.Reported gross margin was 29.2%, an increase of 30 basis points versus the prior year. Adjusted gross margin increased 30 bps to 31.0% due primarily to the same factors as adjusted gross profit.Reported operating loss was $669 million compared to operating income of $270 million in the prior year, due primarily to the Goodwill Impairment charge discussed above. Adjusted operating income decreased $11 million, or 2.6%, to $411 million as Project Energize savings and lower variable employee expenses were more than offset by lower gross profit flow through.Reported operating margin was -25.9%, due primarily to the Goodwill Impairment charge discussed above. Adjusted operating margin of 15.9% expanded 20 basis points versus the prior year due primarily to the same factors as adjusted operating income.Consumer Self-Care International SegmentFiscal Year 2025 Net Sales Change Compared to Prior Year(5)
Reported
Net Sales
GrowthForeign
Exchange
ImpactConstant
Currency Net
SalesDivested
Businesses
and Product
LinesOrganic
Net Sales
GrowthCSCI(0.7) %3.0 %(3.7) %(4.0) %0.3 %CSCI net sales of $1.67 billion decreased 0.7%, or $12 million, as organic net sales growth of 0.3% and favorable currency translation of 3.0% were more than offset by divestitures and exited products of 4.0%.Category drivers included higher organic net sales in 1) Pain and Sleep Aids, led by restored supply of the Solpadeine® brand, 2) Women's Health, led by market share gains in ellaOne®, and 3) Healthy Lifestyle, primarily from new products in the Jungle Formula® franchise. These drivers were partially offset by lower net sales in 1) the VMS category, reflecting reduced strategic focus on nutraceutical products, and 2) Skin Care, due to lower net sales in the ACO® franchise, partially offset by higher net sales and new products in the Compeed® franchise.Reported gross profit of $740 million, decreased $24 million, or 3.1% compared to the prior year. Adjusted gross profit of $846 million decreased $23 million, or 2.6%, as new products, inflation-justified pricing, Supply Chain Reinvention benefits and favorable currency translation of $27 million were more than offset by lower sales volumes, cost of goods sold inflation and $42 million from divestitures and exited products.Reported gross margin was 44.4%, a decrease of 110 basis points versus the prior year. Adjusted gross margin of 50.8% decreased 100 basis points due primarily to the same factors as adjusted gross profit, including an unfavorable impact from divestitures and exited products of 50 basis points.Reported operating loss of $229 million decreased $334 million compared to operating income of $105 million in the prior year, due primarily to the Goodwill Impairment charge discussed above. Adjusted operating income increased $13 million, or 3.7%, to $365 million as Project Energize savings and lower variable employee expenses more than offset unfavorable gross profit flow through and a $21 million impact from divestitures and exited products.Reported operating margin was (13.7)%, due primarily to the Goodwill Impairment charge discussed above. Adjusted operating margin of 21.9%, expanded 90 basis points due primarily to the same factors as adjusted operating income, including an unfavorable impact from divestitures and exited products of 40 basis points.Cash Flow and Balance SheetYear-to-date operating cash flow was $239 million, or cash conversion of 62.5% as a percentage of adjusted net income, including first quarter cash outflow of $(65) million from rebuilding infant formula inventory, settling outstanding litigation and covering Project Energize restructuring costs.Year-to-date capital expenditures were $93 million and the Company returned $159 million to shareholders through dividends.Cash and cash equivalents on the balance sheet as of December 31, 2025, were $532 million and total debt on the balance sheet was $3.64 billion.New Reporting Segments Beginning First Quarter 2026Perrigo Company has changed its reporting segments to better align with the Company's organizational structure and vision. Beginning with the first quarter of 2026, the Company's new reporting segments are:Self Care – Comprises the legacy Upper Respiratory, Digestive Health, Pain & Sleep Aids and Healthy Lifestyles categories, including brands, store brands and contract.Specialty Care – Comprises the legacy Women's Health and Skin Health (formerly Skin Care) categories, including brands, store brands and contract.Infant Formula – Comprises the legacy Infant Formula business, including brands, store brands and contract.In addition, "Other" comprises primarily the Oral Care business, the Dermacosmetics business, which is in the process of being divested, and other small non-core distribution brands.These reporting segment changes have no impact on the Company's historical consolidated financial position, results of operations or cash flows. In order to aid in comparability to historical financial data, the Company will recast selected financial statements and metrics utilizing the new reporting segments. A current report on Form 8-K containing recast information for fiscal 2025 and 2024 is expected to be issued in April 2026.Operational Enhancement ProgramBuilding on the Company's 'Streamlining' actions within its 3–S Plan, it has launched a two-year, enterprise–wide operational enhancement program to create a more agile and resilient platform positioned for growth in our core business. The program is designed to streamline operations in response to near–term industry pressures, including soft consumer consumption leading to lower volumes, while freeing up capital to further invest behind our key brands and store brands.The Company expects the program to enhance organizational effectiveness by evolving its structure to improve agility, accelerate decision–making and better leverage technology. As part of this effort, the Company expects to reduce approximately 7% of its current workforce. The program will also target operational cost reductions mainly in our supply chain and distribution network.The Company anticipates gross pre–tax annualized run rate cost savings of $80 million to $100 million from the program by the end of FY2027, the majority of which are expected to be achieved in FY2026. Cash costs to achieve these savings are expected to range between $80 million and $90 million.Fiscal Year 2026 Outlook from Continuing OperationsBased on current business trends and conditions, and including expected savings from the Company's organizational efficiency program, the Company issued its FY2026 'All In' net sales growth outlook of -5.5% to -1.5% versus the prior year. Its FY2026 "All In" adjusted diluted EPS range outlook is $2.00 to $2.30.The Company also issued its FY2026 outlook for 'CORE' Perrigo, which excludes the infant formula business currently under strategic review and previously announced divestitures, to better reflect its go-forward business. CORE reported net sales and organic net sales growth outlooks are -3.0% to +1.0% and -3.5% to +0.5%, respectively, versus the prior year. FY2026 CORE adjusted EPS outlook of $2.25 to $2.55 compares to FY2025 CORE adjusted EPS of $2.52.FY2026 All In Outlook Walk to FY2026 CORE OutlookFY2026 OutlookNet Sales GrowthAdj. Gross MarginAdj. Operating
MarginAdj. EPSAll In Perrigo-5.5% to -1.5%36.5% to 37.5%12.5% to 13.5%$2.00 to $2.30Exclude Infant
FormulaFlat~240bps~260bps~$0.30Exclude Divestitures~(270)bps~(10)bps~(10)bps~$(0.05)CORE Perrigo-3.0% to +1.0%39.0% to 40.0%15.0% to 16.0%$2.25 to $2.55




Organic CORE-3.5% to +0.5%


Additional FY2026 outlook assumptions include:Interest expense of approximately $156 million.Adjusted effective tax rate of approximately 20.0%.Adjusted weighted average shares outstanding of approximately 140.5 million.Net leverage in line, or slightly better than 2025 of approximately 4.0 times adjusted EBITDA.About PerrigoPerrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers trusted self-care solutions that can be used without the need for a prescription, ensuring accessibility and choice for consumers across molecules, dosage forms, and value tiers.Perrigo's unique business model leverages its complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.For more information, visit www.perrigo.com.Webcast and Conference Call InformationPerrigo previously announced that management will host a call/webcast to discuss its fourth quarter 2025 financial results beginning at 08:30 A.M. (EST) Thursday, February 26, 2026. The call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 52719. A taped replay of the call will be available beginning at approximately 12:00 P.M. (EST) Thursday, February 26, until midnight Thursday, March 5, 2026. To listen to the replay, dial 888-660-6345, International 646-517-4150, and use access code 52719#.Forward-Looking StatementsCertain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this report, including certain statements contained in "Management's Discussion and Analysis of Financial Condition and Results of Operations" are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "forecast," "predict," "potential" or the negative of those terms or other comparable terminology. We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control, including: our ability to complete the proposed divestment of the Dermacosmetics branded business, receipt of works council and regulatory approval regarding the transaction, performance by counterparties to the transaction and the likelihood of satisfying the deferred payment milestones associated with the transaction, supply chain impacts on our business, including those caused or exacerbated by armed conflict, trade and other economic sanctions and/or disease; general economic, credit, and market conditions; increased or new tariffs by the U.S. or foreign governments (and any retaliatory or reciprocal tariffs) and changes in global trade relations; the impact of the war in Ukraine and any escalation thereof, including the effects of economic and political sanctions imposed by the United States, United Kingdom, European Union, and other countries related thereto; the outbreak or escalation of conflict in other regions where we do business, including the Middle East; current and future impairment charges, if we determine that the carrying amount of specific assets may not be recoverable from the expected future cash flows of such assets; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than we do; pricing pressures from customers and consumers; resolution of uncertain tax positions and any litigation relating thereto, ongoing or future government investigations and regulatory initiatives; uncertainty regarding our ability to obtain and maintain our regulatory approvals; potential costs and reputational impact of product recalls or sales halts; potential adverse changes to U.S. and foreign tax, healthcare and other government policy; the effect of epidemic or pandemic disease; the timing, amount and cost of any share repurchases (or the absence thereof) and/or any refinancing of outstanding debt at or prior to maturity; fluctuations in currency exchange rates and interest rates; receipt of potential earnout payments in connection with the sale of the HRA Rare Diseases Business and the risk that potential costs or liabilities incurred or retained in connection with this transaction may exceed our estimates or adversely affect our business or operations; the risk that potential costs or liabilities incurred or retained in connection with the sale of our Rx business may exceed our estimates or adversely affect our business or operations; the consummation and success of other announced and unannounced acquisitions or dispositions, and our ability to realize the desired benefits thereof; and our ability to execute and achieve the desired benefits of announced cost-reduction efforts and other strategic initiatives and investments, including our ability to achieve the expected benefits from our ongoing restructuring programs described herein. Adverse results with respect to pending litigation could have a material adverse impact on our operating results, cash flows and liquidity, and could ultimately require the use of corporate assets to pay damages, reducing assets that would otherwise be available for other corporate purposes. These and other important factors, including those discussed in our Form 10-K for the year ended December 31, 2025, and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.Non-GAAP MeasuresThis press release contains certain non-GAAP measures. A "non-GAAP financial measure" is defined as a numerical measure of a company's financial performance that excludes or includes amounts different from the most directly comparable measure calculated and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP) in the statements of operations, balance sheets or statements of cash flows of the Company. Pursuant to the requirements of the U.S. Securities and Exchange Commission, the Company has provided reconciliations to the most directly comparable U.S. GAAP measures for the following non-GAAP financial measures referred to in this press release:net sales growth on an organic basis, which excludes acquisitions, divestitures and exited products, and the impact of currency,adjusted gross profit,adjusted gross margin,adjusted operating income,adjusted operating margin,adjusted net income,adjusted diluted earnings per share,These non-GAAP financial measures should be considered as supplements to the GAAP reported measures, should not be considered replacements for, or superior to the GAAP measures and may not be comparable to similarly named measures used by other companies. The Company presents these non-GAAP financial measures in order to provide transparency to our investors because they are measures that management uses to assess both management performance and the financial performance of our operations and to allocate resources. In addition, management believes that these measures may assist investors with understanding and evaluating our initiatives to drive improved financial performance and enables investors to supplementally compare our operating performance with the operating performance of our competitors including with those of our competitors having different capital structures. While we have excluded certain of these items from historical non-GAAP financial measures, there is no guarantee that the items excluded from non-GAAP financial measures will not continue into future periods. For instance, we expect to continue to experience and report restructuring-related charges associated with continued execution of our strategic initiatives.The Company provides non-GAAP financial measures as additional information that it believes is useful to investors and analysts in evaluating the performance of the Company's ongoing operating trends, facilitating comparability between periods and, where applicable, with companies in similar industries and assessing the Company's prospects for future performance. These non-GAAP financial measures exclude items, such as amortization expense, unusual litigation, impairment charges, restructuring charges, and acquisition and integration-related charges, that by their nature affect comparability of operational performance or that we believe obscure underlying business operational trends. The intangible asset amortization excluded from these non-GAAP financial measures represents the entire amount recorded within the Company's GAAP financial statements and is excluded because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised. The revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. The non-GAAP measures the Company provides are consistent with how management analyzes and assesses the operating performance of the Company, and disclosing them provides investor insight into management's view of the business. Management uses these adjusted financial measures for planning and forecasting in future periods, and evaluating segment and overall operating performance. In addition, management uses certain of the profit measures as factors in determining compensation.Non-GAAP measures related to profit measurements, which may include adjusted gross profit, adjusted net income, adjusted operating income, adjusted diluted earnings per share, adjusted gross margin, constant currency net sales, and adjusted operating margin are useful to investors as they provide them with supplemental information to enhance their understanding of the Company's underlying business performance and trends, and enhance the ability of investors and analysts to compare the Company's period-to-period financial results. Management believes that adjusted gross margin and adjusted operating margin are useful to investors, in addition to the reasons discussed above, by allowing them to more easily compare and analyze trends in the Company's peer business group and assisting them in comparing the Company's overall performance to that of its competitors. The Company also discloses net sales growth excluding the impact of currency on an organic basis. In addition, the Company presents non–GAAP measures for 'CORE' Perrigo, reflecting its go–forward business and excluding infant formula currently under strategic review and previously announced divestitures. CORE measures may include CORE net income, CORE net sales, CORE organic net sales, CORE gross profit, CORE operating income, CORE diluted earnings per share, CORE gross margin, and CORE operating margin, including on an organic, constant–currency basis. Management believes these measures provide greater consistency in financial reporting and facilitate meaningful comparisons of underlying operating results and acquisition and divestiture activity.The Company cannot reconcile its 'All In' or 'CORE' expected organic net sales growth, adjusted gross margin, adjusted operating margin, adjusted earnings per share, adjusted diluted earnings per share, adjusted effective tax rate, net leverage, or adjusted EBITDA to the most directly comparable GAAP measures under "Fiscal Year 2026 Outlook from Continuing Operations" without unreasonable effort because certain items that impact net income and other reconciling metrics are out of the Company's control and/or cannot be reasonably predicted at this time. These items include, but are not limited to, uncertainty of non-recurring infant formula related charges and timing and amount of restructuring charges and the income tax effects of these items or other income tax-related events.The Company believes these supplemental financial measures provide investors with consistency in financial reporting, enabling meaningful comparisons of past and present underlying operating results, and also facilitate analysis of the Company's operating performance and acquisition and divestiture trends.A copy of this press release, including the reconciliations, is available on the Company's website at www.perrigo.com.Perrigo ContactBradley Joseph, Vice President, Global Investor Relations & Corporate Communications; (269) 686-3373; E-mail: bradley.joseph@perrigo.comNicholas Gallagher, Associate Director, Global Investor Relations; (269) 686-3238, E-mail: nicholas.gallagher@perrigo.com PERRIGO COMPANY PLCCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in millions, except per share amounts)(unaudited)

Three Months Ended
Twelve Months Ended
December 31,
2025
December 31,
2024
December 31,
2025
December 31,
2024Net sales$             1,109.6
$             1,138.3
$             4,253.1
$             4,373.4Cost of sales747.4
752.4
2,758.6
2,830.7Gross profit362.2
385.9
1,494.5
1,542.7







Operating expenses






Distribution22.7
23.3
93.4
98.0Research and development21.8
27.9
95.4
112.2Selling116.5
116.8
526.5
546.6Administration116.5
94.6
435.9
468.0Impairment charges1,358.5
38.6
1,363.1
88.9Restructuring13.0
12.0
71.9
110.1Other operating (income) expense, net0.4
(41.5)
30.5
6.0Total operating expenses1,649.4
271.7
2,616.7
1,429.8







Operating income (loss)(1,287.2)
114.2
(1,122.2)
112.9







Interest expense, net43.3
43.1
162.5
187.8Other (income) expense, net1.2
(0.6)
13.2
(0.9)Loss on extinguishment of debt—
1.5
—
6.7Income (loss) from continuing operations before
income taxes(1,331.7)
70.2
(1,297.9)
(80.7)Income tax expense82.8
111.6
104.4
80.0Loss from continuing operations(1,414.5)
(41.4)
(1,402.3)
(160.7)Loss from discontinued operations, net of tax(3.6)
(3.1)
(23.1)
(11.1)Net income (loss)$           (1,418.1)
$                (44.5)
$           (1,425.4)
$              (171.8)







Earnings (loss) per share






Basic






Continuing operations$              (10.20)
$                (0.30)
$              (10.12)
$                (1.17)Discontinued operations(0.03)
(0.02)
(0.17)
(0.08)Basic earnings (loss) per share$              (10.22)
$                (0.32)
$              (10.29)
$                (1.25)Diluted






Continuing operations$              (10.20)
$                (0.30)
$              (10.12)
$                (1.17)Discontinued operations(0.03)
(0.02)
(0.17)
(0.08)Diluted earnings (loss) per share$              (10.22)
$                (0.32)
$              (10.29)
$                (1.25)







Weighted-average shares outstanding






Basic138.7
137.6
138.5
137.4Diluted138.7
137.6
138.5
137.4 PERRIGO COMPANY PLCCONDENSED CONSOLIDATED BALANCE SHEETS(in millions, except per share amounts)(unaudited)

December 31,
2025
December 31,
2024Assets


Current assets


Cash and cash equivalents$                531.6
$                558.8Accounts receivable, net of allowance for credit losses of $6.5 and $7.4, respectively612.8
642.3Inventories1,149.0
1,081.8Prepaid expenses and other current assets231.4
199.0Current assets held for sale272.6
—Total current assets2,797.4
2,481.9Property, plant and equipment, net898.7
917.8Operating lease assets167.8
175.2Goodwill and indefinite-lived intangible assets2,054.7
3,325.4Definite-lived intangible assets, net2,351.5
2,423.7Deferred income taxes3.3
5.1Other non-current assets261.8
318.6Total non-current assets5,737.8
7,165.8Total assets$             8,535.2
$             9,647.7Liabilities and Shareholders' Equity


Liabilities


Accounts payable$                474.5
$                495.2Payroll and related taxes112.2
123.2Accrued customer programs111.4
133.3Other accrued liabilities230.6
238.7Accrued income taxes20.8
17.4Current indebtedness36.6
36.4Current liabilities held for sale26.8
—Total current liabilities1,012.9
1,044.2Non-current liabilities


Long-term debt, less current portion3,603.6
3,581.7Deferred income taxes168.9
203.2Other non-current liabilities814.3
499.2Total non-current liabilities4,586.8
4,284.1Total liabilities5,599.7
5,328.3Contingencies - Refer to Note 20


Shareholders' equity


Controlling interests:


Preferred shares, $0.0001 par value per share, 10 shares authorized—
—Ordinary shares, €0.001 par value per share, 10,000 shares authorized6,608.2
6,733.9Accumulated other comprehensive income (loss)4.8
(162.4)Retained earnings (accumulated deficit)(3,677.5)
(2,252.1)Total shareholders' equity2,935.5
4,319.4Total liabilities and shareholders' equity$             8,535.2
$             9,647.7



Supplemental Disclosures of Balance Sheet Information


Preferred shares, issued and outstanding—
—Ordinary shares, issued and outstanding137.6
136.5 PERRIGO COMPANY PLCCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in millions)(unaudited)

Year Ended
December 31,
2025
December 31,
2024
December 31,
2023Cash Flows From (For) Operating Activities




Net income (loss)$            (1,425.4)
$               (171.8)
$                  (12.7)Adjustments to derive cash flows:




Depreciation and amortization337.5
325.9
359.5Impairment charges1,363.1
88.9
90.0Share-based compensation54.6
64.4
68.8Restructuring charges67.0
99.9
41.1Settlement of interest rate derivatives —
41.2
—Amortization of debt discount9.0
8.9
2.3Gain (loss) on sale of business1.6
(6.4)
—Gain on sale of assets—
(28.1)
(4.1)Dedesignation of interest rate swap agreements—
14.4
—Amortization on hedging instruments(23.8)
(10.1)
1.7Deferred income taxes(50.8)
9.8
(106.6)Other non-cash adjustments, net6.8
0.6
24.0Subtotal339.6
437.6
464.0(Decrease) increase in cash due to:




Accounts receivable30.7
(11.1)
(57.1)Inventories(61.1)
13.7
19.4Prepaid expenses and other current assets8.4
20.1
47.5Accounts payable(28.7)
54.2
(65.9)Payroll and related taxes(63.4)
(94.4)
(52.8)Accrued customer programs(26.2)
(25.6)
23.2Other accrued liabilities (16.5)
(1.3)
6.6Accrued income taxes55.9
(31.8)
(12.9)Other long term liabilities(0.2)
—
7.6Other operating, net —
1.5
25.9Subtotal(101.1)
(74.7)
(58.5)Net cash from operating activities238.5
362.9
405.5Cash Flows From (For) Investing Activities




Proceeds from royalty rights5.6
5.2
19.8Asset acquisitions, net(1.5)
(13.3)
—Settlement of foreign currency derivatives—
(48.2)
—Proceeds from sale of assets—
37.9
4.4Additions to property, plant and equipment(93.4)
(118.3)
(101.7)Net proceeds from sale of businesses14.4
215.5
—Other investing, net(0.5)
—
—Net cash (for) from investing activities(75.4)
78.8
(77.5)Cash Flows From (For) Financing Activities




Issuances of long-term debt—
1,091.2
295.1Payments on long-term debt(34.8)
(1,529.0)
(325.3)Payments for debt issuance costs—
(4.7)
—Cash dividends(159.3)
(152.5)
(149.7)Shares used to settle taxes(19.1)
(15.5)
(18.8)Other financing, net(7.3)
(0.5)
11.5Net cash for financing activities(220.5)
(611.0)
(187.2)Effect of exchange rate changes on cash and cash equivalents32.5
(23.2)
9.8Net (decrease) increase in cash and cash equivalents(24.9)
(192.5)
150.6Cash and cash equivalents of continuing operations, beginning of period558.8
751.3
600.7Cash and cash equivalents held for sale, beginning of period—
—
—Less cash and cash equivalents held for sale, end of period(2.3)
—
—Cash and cash equivalents of continuing operations, end of period$                 531.6
$                 558.8
$                 751.3 TABLE IPERRIGO COMPANY PLCRECONCILIATION OF NON-GAAP MEASURESSELECTED CONSOLIDATED INFORMATION(in millions, except per share amounts)(unaudited)

Three Months Ended December 31, 2025
Three Months Ended December 31, 2024Consolidated Continuing OperationsGross ProfitOperating
Income (Loss)Income (Loss)
from Continuing
Operations(1)Diluted Earnings
(Loss) per
Share(1)
GrossProfitOperating
IncomeIncome (Loss)
from Continuing
Operations(1)Diluted Earnings
(Loss) per
Share(1)Reported$            362.2$        (1,287.2)$         (1,414.5)$                (10.20)
$            385.9$            114.2$              (41.4)$                 (0.30)As a % of reported net sales(2) 32.6 %(116.0) %(127.5) %

33.9 %10.0 %(3.6) %
Pre-tax adjustments:








Amortization expense related primarily to acquired
intangible assets 35.855.755.70.40
33.455.455.90.40Unusual litigation—19.719.70.14
—(33.9)(33.9)(0.25)Restructuring charges and other termination benefits —13.013.00.09
0.713.313.30.10(Gain) loss on divestitures and brand sales——0.90.01
—(2.2)(2.8)(0.02)Impairment charges (3)—1,358.51,358.59.78
—38.638.60.28Infant formula remediation————
3.83.93.90.03Loss on early debt extinguishment————
——1.50.01Other (4) 3.17.47.00.05
—4.64.60.03Non-GAAP tax adjustments(5) ——67.40.48
——89.20.64Adjusted$            401.1$            167.2$              107.6$                   0.77
$            423.9$            193.9$              128.7$                   0.93As a % of reported net sales(2) 36.1 %15.1 %9.7 %

37.2 %17.0 %11.3 %










Diluted weighted average shares outstanding (in millions)








Reported138.7



137.6Effect of dilution as reported amount was a loss, while adjusted amount was income(6)0.3



0.7


Adjusted139.0



138.3Note: Amounts may not add or recalculate due to rounding. Percentages are based on actuals.
(1)Individual pre-tax line item adjustments have not been tax effected, as tax expense on these items are aggregated in the "Non-GAAP tax adjustments" line item.(2)Reported net sales for the three months ended December 31, 2025 and December 31, 2024 were $1,109.6 million and $1,138.3 million, respectively.(3)During the three months ended December 31, 2025, impairment charges were due primarily to (1) we determined the carrying value of our CSCA and CSCI reporting units exceeded their estimated fair value and recorded a goodwill impairment charge of $1.3 billion and (2) we concluded the existence of an other-than-temporary impairment of our equity method investment in Kazmira LLC and recorded an impairment charge of $33.6 million within our CSCA segment. During the three months ended December 31, 2024, we determined the carrying value of our Prevacid® branded product was impaired by $38.6 million and recorded the charge within our CSCA segment.(4)Other pre-tax adjustments for the three months ended December 31, 2025 includes $3.8 million of professional consulting fees for potential divestiture activity and $3.2 million of accelerated depreciation. Other pre-tax adjustments for the three months ended December 31, 2024 are primarily due to $4.0 million related to professional consulting fees for divestiture activity.(5)Non-GAAP tax adjustments for the three months ended December 31, 2025 are primarily due to (1) removal of $11.2 million of tax expense on pre-tax non-GAAP adjustments, (2) removal of $4.7 million of tax benefit related to changes in the tax law enacted in fourth quarter 2025, and (3) removal of $33.3 million of tax expense related to uncertain tax positions from changes in tax structure and (4) removal of $26.7 million of tax expense related to recording the U.S. valuation allowance. Non-GAAP tax adjustments for the three months ended December 31, 2024 are primarily due to $24.8 million of tax expense on pre-tax non-GAAP adjustments, plus the removal of (1) $110.6 million of tax impact related to an inter-company sale of intellectual property and (2) $3.1 million of tax expense related to audit adjustments.(6)In the period of a net loss, reported diluted shares outstanding equal basic shares outstanding. TABLE I (Continued) PERRIGO COMPANY PLCRECONCILIATION OF NON-GAAP MEASURESSELECTED CONSOLIDATED INFORMATION(in millions, except per share amounts)(unaudited)

Twelve Months Ended December 31, 2025
Twelve Months Ended December 31, 2024Consolidated Continuing OperationsGrossProfitOperating
Income (Loss)Income (Loss)
from Continuing
Operations(1)Diluted Earnings
(Loss) per
Share(1)
GrossProfitOperating
IncomeIncome (Loss)
from Continuing
Operations(1)Diluted Earnings
(Loss) per
Share(1)Reported$         1,494.5$        (1,122.2)$         (1,402.3)$                (10.12)
$         1,542.7$            112.9$            (160.7)$                 (1.17)As a % of reported net sales(2) 35.1 %(26.4) %(33.0) %

35.3 %2.6 %(3.7) %
Pre-tax adjustments:








Amortization expense related primarily to acquired
intangible assets 141.1223.5225.01.62
135.0229.5231.71.69Restructuring charges and other termination benefits—71.971.90.52
2.7113.4113.40.82Unusual litigation—59.059.00.43
—54.254.20.39Impairment charges(3)—1,363.11,363.19.84
—88.988.90.65(Gain) loss on divestitures and brand sales——2.70.02
—(28.1)(34.5)(0.26)Infant formula remediation0.90.90.90.01
17.521.721.70.16Loss on early debt extinguishment————
——6.70.05Other(4)11.526.134.90.25
—16.031.90.23Non-GAAP tax adjustments(5)——26.20.19
——0.90.01Adjusted$         1,648.0$            622.3$              381.6$                   2.75
$         1,697.9$            608.5$              354.0$                   2.57As a % of reported net sales(2)38.7 %14.6 %9.0 %

38.8 %13.9 %8.1 %










Diluted weighted average shares outstanding (in millions)








Reported138.5



137.4Effect of dilution as reported amount was a loss, while adjusted amount was income(6)0.4



0.6


Adjusted138.9



138.0Note: Amounts may not add or recalculate due to rounding. Percentages are based on actuals.
(1)Individual pre-tax line item adjustments have not been tax effected, as tax expense on these items are aggregated in the "Non-GAAP tax adjustments" line item.(2)Reported net sales for the twelve months ended December 31, 2025 and December 31, 2024 were $4,253.1 million and $4,373.4 million, respectively.(3)During the twelve months ended December 31, 2025, impairment charges were due primarily to (1) we determined the carrying value of our CSCA and CSCI reporting units exceeded their estimated fair value, resulting in a total goodwill impairment of $1.3 billion and (2) we concluded the existence of an other-than-temporary impairment of our equity method investment in Kazmira LLC and recorded an impairment charge of $33.6 million within our CSCA segment. During the twelve months ended December 31, 2024, we determined the carrying value of the Rare Disease Business net assets exceeded their fair value less cost to sell, resulting in a total impairment charge of $34.1 million, inclusive of a goodwill impairment charge of $22.1 million, we also determined the carrying value of the Hospital & Specialty Business net assets exceeded their fair value less costs to sell, resulting in a total impairment charge of $16.2 million, inclusive of a goodwill impairment charge of $5.4 million, and recorded the charges for each within our CSCI segment; we also determined the carrying value of our Prevacid® branded product was impaired by $38.6 million and recorded the charge within our CSCA segment.(4)Other pre-tax adjustments for the twelve months ended December 31, 2025 are due primarily to $12.2 million of professional consulting fees for potential divestiture activity, $9.2 million of foreign currency hedging related to divestiture activity, $11.9 million of accelerated depreciation and a $1.6 million asset abandonment related to our Nutrition Network Optimization Project. Other pre-tax adjustments for the twelve months ended December 31, 2024 includes expenses of $14.4 million related to de-designation of interest rate swap agreements, amounts related to professional consulting fees for divestiture activity and amounts related to a foreign jurisdiction transfer tax payment.(5)Non-GAAP tax adjustments for the twelve months ended December 31, 2025 are primarily due to (1) removal of $57.2 million of tax expense related to uncertain tax positions from changes in tax structure, (2) removal of $34.3 million of tax benefit on pre-tax non-GAAP adjustments (3) removal of $26.7 million of tax expense related to recording the U.S. valuation allowance, and (4) removal of $24.2 million of tax benefit related to changes in tax laws enacted in 2025. Non-GAAP tax adjustments for the twelve months ended December 31, 2024 are primarily due to (1) removal of $57.2 million of tax expense related to uncertain tax positions from changes in tax structure, (2) removal of $34.3 million of tax benefit on pre-tax non-GAAP adjustments (3) removal of $26.7 million of tax expense related to recording the U.S. valuation allowance, and (4) removal of $24.2 million of tax benefit related to changes in tax laws enacted in 2025.(6)In the period of a net loss, reported diluted shares outstanding equal basic shares outstanding. TABLE II PERRIGO COMPANY PLCRECONCILIATION OF NON-GAAP MEASURESSELECTED CONSOLIDATED INFORMATION(in millions, except per share amounts)(unaudited)

Three Months Ended December 31, 2025
Three Months Ended December 31, 2024Consolidated Continuing OperationsR&D ExpenseDSG&A
ExpenseRestructuring,
Impairments
and Other
R&D ExpenseDSG&A
Expense (4)Restructuring,
Impairments
and Other (4)Reported$              21.8$            255.7$         1,371.9
$              27.9$            234.7$                9.1As a % of reported net sales(1)2.0 %23.0 %123.6 %
2.5 %20.6 %0.8 %Pre-tax adjustments:






Amortization expense related primarily to acquired
intangible assets (0.1)(19.7)—
(0.4)(21.6)—Unusual litigation—(19.3)(0.4)
——33.9Restructuring charges and other termination benefits——(13.0)
—(0.6)(12.0)Impairment charges(2)——(1,358.5)
——(38.6)(Gain) loss on divestitures and brand sales———
——2.2Other (3) (0.1)(4.1)—
—(10.0)5.4Adjusted$              21.5$            212.4$                  —
$              27.5$            202.5$                  —As a % of reported net sales (1)1.9 %19.1 %— %
2.4 %17.8 %— %Note: Amounts may not add or recalculate due to rounding. Percentages are based on actuals.
(1)Reported net sales for the three months ended December 31, 2025 and December 31, 2024 were $1,109.6 million and $1,138.3 million, respectively.(2)During the twelve months ended December 31, 2025 impairment charges were due primarily to (1) we determined the carrying value of our CSCA and CSCI reporting units exceeded their estimated fair value, resulting in a total goodwill impairment of $1.3 billion and (2) we concluded the existence of an other-than-temporary impairment of our equity method investment in Kazmira LLC and recorded an impairment charge of $33.6 million within our CSCA segment. During the three months ended December 31, 2024, we determined the carrying value of our Prevacid® branded product was impaired by $38.6 million and recorded the charge within our CSCA segment.(3)Other pre-tax adjustments for the three months ended December 31, 2025 are primarily due to professional consulting fees for potential divestitures. Other pre-tax adjustments for the three months ended December 31, 2024 is due primarily to $4.0 million related to professional consulting fees.(4)Certain prior period amounts have been reclassified from DSG&A Expense to Restructuring, Impairments and Other for comparability purposes.  TABLE II (Continued)PERRIGO COMPANY PLCRECONCILIATION OF NON-GAAP MEASURESSELECTED CONSOLIDATED INFORMATION(in millions, except per share amounts)(unaudited)

Twelve Months Ended December 31, 2025
Twelve Months Ended December 31, 2024Consolidated Continuing OperationsR&D ExpenseDSG&A
ExpenseRestructuring,
Impairments
and Other
R&D ExpenseDSG&A
Expense (4)Restructuring,
Impairments
and Other (4)Reported$              95.4$         1,055.8$         1,465.5
$            112.2$         1,112.6$            205.0As a % of reported net sales (1)2.2 %24.8 %34.5 %
2.6 %25.4 %4.7 %Pre-tax adjustments:






Amortization expense related primarily to acquired
intangible assets(0.6)(81.8)—
(1.1)(93.5)—Restructuring charges and other termination benefits——(71.9)
—(0.8)(109.9)Unusual litigation—(28.5)(30.5)
——(54.2)Impairment charges(2)——(1,363.1)
——(88.9)Infant formula remediation———
—(4.2)—(Gain) loss on divestitures and brand sales———
——28.1Other(3)(0.4)(14.2)—
—(35.9)20.1Adjusted$              94.5$            931.2$                  —
$            111.1$            978.1$                0.2As a % of reported net sales (1)2.2 %21.9 %— %
2.5 %22.4 %— %Note: Amounts may not add or recalculate due to rounding. Percentages are based on actuals.
(1)Reported net sales for the twelve months ended December 31, 2025 and December 31, 2024 were $4,253.1 million and $4,373.4 million, respectively.(2)During the twelve months ended December 31, 2025, impairment charges were due primarily to (1) we determined the carrying value of our CSCA and CSCI reporting units exceeded their estimated fair value, resulting in a total goodwill impairment of $1.3 billion and (2) we concluded the existence of an other-than-temporary impairment of our equity method investment in Kazmira LLC and recorded an impairment charge of $33.6 million within our CSCA segment. During the twelve months ended December 31, 2024, we determined the carrying value of the Rare Disease Business net assets exceeded their fair value less cost to sell, resulting in a total impairment charge of $34.1 million, inclusive of a goodwill impairment charge of $22.1 million, we also determined the carrying value of the Hospital & Specialty Business net assets exceeded their fair value less costs to sell, resulting in a total impairment charge of $16.2 million, inclusive of a goodwill impairment charge of $5.4 million, recording the charges within our CSCI segment, and we determined the carrying value of our Prevacid® branded product was impaired by $38.6 million and recorded the charge within our CSCA segment.(3)Other pre-tax adjustments for the twelve months ended December 31, 2025 are due primarily to $12.2 million of professional consulting fees for potential divestiture activity. Other pre-tax adjustments for the twelve months ended December 31, 2024 are due primarily to professional consulting fees for divestiture activity.(4)Certain prior period amounts have been reclassified from DSG&A Expense to Restructuring, Impairments and Other for comparability purposes.  TABLE IIIPERRIGO COMPANY PLCRECONCILIATION OF NON-GAAP MEASURESSELECTED CONSOLIDATED INFORMATION(in millions, except per share amounts)(unaudited)

Three Months Ended December 31, 2025
Three Months Ended December 31, 2024Consolidated Continuing OperationsInterest and OtherIncome Tax Expense
Interest and Other Income Tax ExpenseReported$                          44.5$                          82.8
$                        44.0$                      111.6As a % of reported net sales (1)4.0 %7.5 %
3.9 %9.8 %Effective tax rate
(6.2) %

159.1 %Pre-tax adjustments:




Loss on divestitures(0.9)—
0.6—Loss on early debt extinguishment——
(1.5)—Amortization expense related primarily to acquired
intangible assets ——
(0.5)—Other0.4—
——Non-GAAP tax adjustments(2) —(67.4)
—(89.2)Adjusted$                          44.1$                          15.5
$                        42.6$                        22.6As a % of reported net sales (1)4.0 %1.4 %
3.7 %2.0 %Adjusted effective tax rate
12.6 %

14.8 %Note: Amounts may not add or recalculate due to rounding. Percentages are based on actuals.
(1)Reported net sales for the three months ended December 31, 2025 and December 31, 2024 were $1,109.6 million and $1,138.3 million, respectively.(2)Non-GAAP tax adjustments for the three months ended December 31, 2025 are primarily due to (1) removal of $11.2 million of tax expense on pre-tax non-GAAP adjustments, (2) removal of $4.7 million of tax benefit related to changes in the tax law enacted in fourth quarter 2025, and (3) removal of $33.3 million of tax expense related to uncertain tax positions from changes in tax structure and (4) removal of $26.7 million of tax expense related to recording the U.S. valuation allowance. Non-GAAP tax adjustments for the three months ended December 31, 2024 are primarily due to $24.8 million of tax expense on pre-tax non-GAAP adjustments, plus the removal of (1) $110.6 million of tax impact related to an inter-company sale of intellectual property and (2) $3.1 million of tax expense related to audit adjustments. TABLE III (Continued)PERRIGO COMPANY PLCRECONCILIATION OF NON-GAAP MEASURESSELECTED CONSOLIDATED INFORMATION(in millions, except per share amounts)(unaudited)

Twelve Months Ended December 31, 2025
Twelve Months Ended December 31, 2024Consolidated Continuing OperationsInterest and OtherIncome Tax Expense
Interest and Other Income Tax Expense Reported$                      175.7$                      104.4
$                      193.6$                        80.0As a % of reported net sales (1)4.1 %2.5 %
4.4 %1.8 %Effective tax rate
(8.0) %

(99.3) %Pre-tax adjustments:




Amortization expense primarily related to acquired
intangible assets(1.5)—
(2.2)—Loss on early debt extinguishment——
(6.7)—(Gain) loss on divestitures and brand sales(2.7)—
6.4—Other(2)(8.8)—
(15.8)—Non-GAAP tax adjustments(3)—(26.2)
—(0.9)Adjusted$                      162.6$                        78.2
$                      175.2$                        79.3As a % of reported net sales (1)3.8 %1.8 %
4.0 %1.8 %Adjusted effective tax rate
17.0 %

18.3 %Note: Amounts may not add or recalculate due to rounding. Percentages are based on actuals.

(1)Reported net sales for the twelve months ended December 31, 2025 and December 31, 2024 were $4,253.1 million and $4,373.4 million, respectively.(2)Other pre-tax adjustments for the twelve months ended December 31, 2025 are due primarily to foreign currency hedging related to divestiture activity. Other pre-tax adjustments for the twelve months ended December 31, 2024 are primarily due to expenses of $14.4 million related to de-designation of interest rate swap agreements.(3)Non-GAAP tax adjustments for the twelve months ended December 31, 2025 are primarily due to (1) removal of $57.2 million of tax expense related to uncertain tax positions from changes in tax structure, (2) removal of $34.3 million of tax benefit on pre-tax non-GAAP adjustments (3) removal of $26.7 million of tax expense related to recording the U.S. valuation allowance, and (4) removal of $24.2 million of tax benefit related to changes in tax laws enacted in 2025. Non-GAAP tax adjustments for the twelve months ended December 31, 2024 are primarily due to $62.7 million of tax expense on pre-tax non-GAAP adjustments, the interim tax accounting requirements in ASC 740 – Income Taxes, which include the removal of (1) $65.9 million tax impact related to an inter-company sale of intellectual property, (2) $3.5 million of tax benefit related to a partial valuation allowance release in Belgium, and (3) $2.1 million of tax benefit related to audit adjustments. TABLE IVPERRIGO COMPANY PLCRECONCILIATION OF NON-GAAP MEASURESSELECTED SEGMENT INFORMATION(in millions)(unaudited)

Three Months Ended December 31, 2025
Three Months Ended December 31, 2024Consumer Self-Care AmericasGross ProfitR&D
ExpenseDSG&A
ExpenseOperating Income (Loss)
Gross ProfitR&D
ExpenseDSG&A
ExpenseOperating Income Reported$   186.5$     12.4$     93.5$             (872.7)
$   216.6$     14.4$     75.8$     82.9As a % of reported net sales(1)26.8 %1.8 %13.4 %(125.2) %
29.1 %1.9 %10.2 %11.1 %Pre-tax adjustments:








Amortization expense related primarily to acquired intangible assets9.1—(6.2)15.3
8.4—(6.3)14.6Restructuring charges and other termination benefits———1.8
0.4——6.9Unusual litigation——(17.7)17.7
————Infant formula remediation————
3.8——3.9Impairment charges (2)———951.5
———38.6Other 2.9(0.1)—3.0
——(0.6)(1.1)Adjusted$   198.5$     12.3$     69.6$              116.5
$   229.1$     14.4$     68.9$   145.8As a % of reported net sales(1)28.5 %1.8 %10.0 %16.7 %
30.8 %1.9 %9.3 %19.6 %

Three Months Ended December 31, 2025
Three Months Ended December 31, 2024Consumer Self-Care InternationalGross ProfitR&D
ExpenseDSG&A
ExpenseOperating
Income (Loss)
Gross ProfitR&D
ExpenseDSG&A
Expense(3)Operating
IncomeReported$   175.7$       9.4$   117.3$           (365.0)
$   169.3$     13.5$   110.9$     39.9As a % of reported net sales(1)42.6 %2.3 %28.5 %(88.5) %
43.0 %3.4 %28.1 %10.1 %Pre-tax adjustments:








Amortization expense related primarily to acquired intangible assets26.7(0.1)(13.5)40.4
25.1(0.3)(15.3)40.7Impairment charges (2)———407.1
————Restructuring charges and other termination benefits———6.8
———5.0Gain on divestitures and brand sales————
——2.2(2.2)Other0.3——0.3
————Adjusted$   202.7$       9.2$   103.9$              89.6
$   194.4$     13.2$     97.8$     83.4As a % of reported net sales(1)49.1 %2.2 %25.2 %21.7 %
49.3 %3.3 %24.8 %21.2 %Note: Amounts may not add or recalculate due to rounding. Percentages are based on actuals.

(1)CSCA reported net sales for the three months ended December 31, 2025 and December 31, 2024 were $697.0 million and $744.1 million, respectively. CSCI reported net sales for the three months ended December 31, 2025 and December 31, 2024 were $412.6 million and $394.1 million, respectively.(2)During the three months ended December 31, 2025, impairment charges were due primarily to (1) we determined the carrying value of our CSCA and CSCI reporting units exceeded their estimated fair value and recorded a goodwill impairment charge of $917.1 million and $407.1 million, respectively and (2) we concluded the existence of an other-than-temporary impairment of our equity method investment in Kazmira LLC and recorded an impairment charge of $33.6 million within our CSCA segment. During the three months ended December 31, 2024, we determined the carrying value of our Prevacid® branded product was impaired by $38.6 million and recorded the charge within our CSCA segment.(3)Certain prior period amounts have been reclassified from DSG&A Expense to Restructuring, Impairments and Other for comparability purposes.  TABLE IV (Continued)PERRIGO COMPANY PLCRECONCILIATION OF NON-GAAP MEASURESSELECTED SEGMENT INFORMATION(in millions)(unaudited)

Twelve Months Ended December 31, 2025
Twelve Months Ended December 31, 2024Consumer Self-Care AmericasGross
ProfitR&D
ExpenseDSG&A
ExpenseOperating
Income (Loss)
Gross
ProfitR&D
ExpenseDSG&A
ExpenseOperating
Income Reported$   754.9$     52.9$   382.5$         (669.0)
$   779.1$     60.0$   381.7$   269.9As a % of reported net sales (1)29.2 %2.0 %14.8 %(25.9) %
28.9 %2.2 %14.2 %10.0 %Pre-tax adjustments:








Amortization expense related primarily to acquired intangible assets34.9—(24.7)59.6
29.4—(30.1)59.5Restructuring charges and other termination benefits———34.0
2.7——31.4Impairment charges (2)———952.9
———38.6Infant formula remediation0.9——0.9
17.5—(4.2)21.7Unusual litigation——(17.7)19.3
————Other (3)11.1(0.4)(1.5)13.0
——(0.8)0.8Adjusted$   801.8$     52.5$   338.6$           410.7
$   828.6$     60.0$   346.6$   421.9As a % of reported net sales (1)31.0 %2.0 %13.1 %15.9 %
30.8 %2.2 %12.9 %15.7 %

Twelve Months Ended December 31, 2025
Twelve Months Ended December 31, 2024Consumer Self-Care InternationalGross ProfitR&D
ExpenseDSG&A
ExpenseOperating
Income (Loss)
Gross
ProfitR&D
ExpenseDSG&A
Expense(4)Operating
IncomeReported$   739.7$     42.5$   496.1$         (228.8)
$   763.5$     52.2$   528.1$   105.0As a % of reported net sales (1)44.4 %2.6 %29.8 %(13.7) %
45.5 %3.1 %31.4 %6.3 %Pre-tax adjustments:








Amortization expense related primarily to acquired intangible assets106.3(0.5)(57.0)163.9
105.5(1.1)(63.4)170.0Restructuring charges and other termination benefits———19.6
———53.8Impairment charges (2)———410.2
———50.3Gain on divestitures and brand sales————
——27.4(27.3)Other0.4——0.4
————Adjusted$   846.4$     42.0$   439.2$          365.3
$   869.1$     51.0$   492.1$   352.1As a % of reported net sales (1)50.8 %2.5 %26.3 %21.9 %
51.7 %3.0 %29.3 %21.0 %Note: Amounts may not add or recalculate due to rounding. Percentages are based on actuals.
(1)CSCA reported net sales for the twelve months ended December 31, 2025 and December 31, 2024 were $2,585.3 million and $2,693.7 million, respectively. CSCI reported net sales for the twelve months ended December 31, 2025 and December 31, 2024 were $1,667.7 million and $1,679.6 million, respectively.(2)During the twelve months ended December 31, 2025, impairment charges were due primarily to (1) we determined the carrying value of our CSCA and CSCI reporting units exceeded their estimated fair value, resulting in a total goodwill impairment of $917.1 million and $407.1 million, respectively and (2) we concluded the existence of an other-than-temporary impairment of our equity method investment in Kazmira LLC and recorded an impairment charge of $33.6 million within our CSCA segment. During the twelve months ended December 31, 2024, we determined the carrying value of the Rare Disease Business net assets exceeded their fair value less cost to sell, resulting in a total impairment charge of $34.1 million, inclusive of a goodwill impairment charge of $22.1 million, we also determined the carrying value of the Hospital & Specialty Business net assets exceeded their fair value less costs to sell, resulting in a total impairment charge of $16.2 million, inclusive of a goodwill impairment charge of $5.4 million, and recorded the charges for each within our CSCI segment; we also determined the carrying value of our Prevacid® branded product was impaired by $38.6 million and recorded the charge within our CSCA segment.(3)Other pre-tax adjustments for the twelve months ended December 31, 2025 includes accelerated depreciation and an asset abandonment related to our Nutrition Network Optimization Project.(4)Certain prior period amounts have been reclassified from DSG&A Expense to Restructuring, Impairments and Other for comparability purposes.  TABLE VPERRIGO COMPANY PLCRECONCILIATION OF NON-GAAP MEASURESCONSOLIDATED AND SELECTED SEGMENT INFORMATION(in millions, except per share amounts)(unaudited)

Three Months Ended


Twelve Months Ended

Consolidated Continuing OperationsDecember 31,
2025
December 31,
2024
% Change
December 31,
2025
December 31,
2024
% ChangeNet Sales $             1,109.6
$             1,138.3
(2.5) %
$             4,253.1
$             4,373.4
(2.8) %Less: Currency impact(1)26.7
—
2.3 %
49.8
—
1.1 %Constant currency net sales $             1,082.9
$             1,138.3
(4.9) %
$             4,203.3
$             4,373.4
(3.9) %Less: Divestitures(2)—
4.3
(0.4) %
—
66.5
(1.5) %Organic net sales $             1,082.9
$             1,134.0
(4.5) %
$             4,203.3
$             4,306.9
(2.4) %

Three Months Ended


Twelve Months Ended

Consumer Self-Care AmericasDecember 31,
2025
December 31,
2024
% Change
December 31,
2025
December 31,
2024
% Change Net Sales $                697.0
$                744.1
(6.3) %
$             2,585.3
$             2,693.7
(4.0) %Less: Currency impact(1)—
—
— %
(0.6)
—
— %Constant currency net sales $                697.0
$                744.1
(6.3) %
$             2,585.9
$             2,693.7
(4.0) %Organic net sales $                697.0
$                744.1
(6.3) %
$             2,585.9
$             2,693.7
(4.0) %

Three Months Ended


Twelve Months Ended

Consumer Self-Care InternationalDecember 31,
2025
December 31,
2024
% Change
December 31,
2025
December 31,
2024
% Change Net Sales $                412.6
$                394.1
4.7 %
$             1,667.7
$             1,679.6
(0.7) %Less: Currency impact(1)26.7
—
6.8 %
50.4
—
3.0 %Constant currency net sales $                385.9
$                394.1
(2.1) %
$             1,617.4
$             1,679.6
(3.7) %Less: Divestitures(2)—
4.3
(1.1) %
—
66.5
(4.0) %Organic net sales $                385.9
$                389.8
(1.0) %
$             1,617.4
$             1,613.1
0.3 %Note: Amounts may not add or recalculate due to rounding. Percentages are based on actuals.
(1)Currency impact is calculated using the exchange rates used to translate our financial statements in the comparable prior year period to show what current period US dollar results would have been if such currency exchange rates had not changed.(2)Represents divestiture of the Rare Diseases Business, Hospital and Specialty Business, Richard Bittner Business and branded asset sales in CSCI. TABLE VIPERRIGO COMPANY PLCRECONCILIATION OF NON-GAAP MEASURESSELECTED SEGMENT INFORMATION(in millions, except per share amounts)(unaudited)

Three Months Ended




Twelve Months Ended




CSCA Net SalesDecember 31,
2025
December 31,
2024
Change
December 31,
2025
December 31,
2024
Change
Upper Respiratory$                  139.1
$                     130.3
$          8.8
6.7 %
$                  529.5
$                  500.3
$          29.1
5.8 %
Digestive Health123.8
135.7
(11.9)
(8.8) %
442.1
497.4
(55.4)
(11.1) %
Nutrition108.4
145.7
(37.2)
(25.6) %
408.5
449.5
(41.0)
(9.1) %
Healthy Lifestyle94.9
85.5
9.3
10.9 %
316.4
306.8
9.5
3.1 %
Pain and Sleep-Aids87.1
93.6
(6.5)
(6.9) %
332.5
345.5
(12.9)
(3.7) %
Oral Care72.2
70.6
1.6
2.3 %
256.9
275.4
(18.6)
(6.7) %
Skin Care49.7
61.5
(11.8)
(19.2) %
214.9
220.1
(5.2)
(2.4) %
Women's Health19.7
19.1
0.5
2.8 %
72.4
81.1
(8.7)
(10.7) %
VMS and Other CSCA2.2
2.1
0.1
4.8 %
12.0
17.6
(5.6)
(31.8) %
Total CSCA Net Sales$                  697.0
$                     744.1
$      (47.1)
(6.3) %
$               2,585.3
$               2,693.7
$      (108.3)
(4.0) %
Note: Amounts may not add or recalculate due to rounding. Percentages are based on actuals.CSCA Year-to-Date Primary Category Drivers:Upper Respiratory: Net sales of $529.5 million increased 5.8% due primarily to increased distribution of both cough cold and allergy products, higher first-quarter incidence levels of cough cold compared to the prior year leading to higher net sales, and greater sell-in to customers of cough cold products in the fourth quarter.Digestive Health: Net sales of $442.1 million decreased 11.1% due primarily to lower consumption of proton pump inhibitors for heartburn, as well as the net impact of pricing actions, which were partially offset by higher net sales in laxatives, including Polyethylene Glycol 3350.Nutrition: Net sales of $408.5 million decreased 9.1% due primarily to infant formula driven by previously disclosed lost distribution of the Good Start® brand and lower contract manufacturing volumes, partially offset by double-digit growth in store brand infant formula.Pain & Sleep-Aids: Net sales of $332.5 million decreased 3.7% due primarily to net lost distribution of lower margin products, lower category consumption of children's analgesics medicines and lower dollar share compared to prior year, partially offset by new business awards.Healthy Lifestyle: Net sales of $316.4 million increased 3.1% due primarily to new distribution wins and increased consumer demand for smoking cessation products.Oral Care: Net sales of $256.9 million decreased 6.7% due primarily to previously disclosed lost distribution of lower-margin products as the business focused on enhancing margin while balancing the unfavorable impacts of tariffs.Skin Care: Net sales of $214.9 million decreased 2.4% due primarily to lower distribution of Minoxidil at one customer, partially offset by growth in the Mederma® brand.Women's Health: Net sales of $72.4 million decreased 10.7% due primarily to the prior year reflecting the strong initial retailer stocking of Opill®, which launched in March 2024, of $15.0 million.Vitamins, Minerals, and Supplements ("VMS") and Other: Net sales of $12.0 million decreased 31.8% due primarily to volume declines in the VMS category. TABLE VI (Continued)PERRIGO COMPANY PLCRECONCILIATION OF NON-GAAP MEASURESSELECTED SEGMENT INFORMATION(in millions, except per share amounts)(unaudited)

Three Months Ended




Constant
Currency
Change (1)
Twelve Months Ended




Constant
Currency
Change (1)CSCI Net SalesDecember 31,
2025
December 31,
2024
%
Change
Less:
Currency
Impact (1)

December 31,
2025
December 31,
2024
%
Change
Less:
Currency
Impact (1)
Skin Care$                  81.6
$                 76.6
6.5 %
7.5 %
(1.0) %
$               407.7
$               410.0
(0.6) %
2.4 %
(3.0) %Upper Respiratory78.7
76.2
3.3 %
7.9 %
(4.5) %
288.2
282.1
2.1 %
4.0 %
(1.9) %Pain and Sleep-Aids62.0
63.6
(2.4) %
5.6 %
(8.0) %
235.4
222.2
6.0 %
4.0 %
2.0 %Healthy Lifestyle51.3
50.5
1.5 %
2.4 %
(0.9) %
231.5
225.8
2.5 %
0.6 %
1.9 %VMS44.9
46.0
(2.3) %
8.1 %
(10.4) %
161.2
173.5
(7.1) %
3.9 %
(11.0) %Women's Health40.2
31.7
26.7 %
9.2 %
17.5 %
143.5
132.8
8.0 %
4.2 %
3.8 %Oral Care25.9
24.4
6.1 %
7.0 %
(0.9) %
97.5
99.4
(2.0) %
3.9 %
(5.9) %Digestive Health and Other
CSCI27.9
25.1
11.4 %
7.3 %
4.1 %
102.7
133.8
(23.2) %
2.1 %
(23.2) %Total CSCI Net Sales$                412.6
$               394.1
4.7 %
6.8 %
(2.1) %
$            1,667.7
$            1,679.6
(0.7) %
3.0 %
(3.7) %Note: Amounts may not add or recalculate due to rounding. Percentages are based on actuals.
(1)Currency impact is calculated using the exchange rates used to translate our financial statements in the comparable prior year period to show what current period US dollar results would have been if such currency exchange rates had not changed.CSCI Year-to-Date Primary Category Drivers:Skin Care: Net sales of $407.7 million decreased 0.6%, inclusive of a 2.4% favorable effect of currency translation, due primarily to lower net sales in the ACO® franchise, partially offset by higher net sales and new products in the Compeed® franchise.Upper Respiratory: Net sales of $288.2 million increased 2.1%, inclusive of a 4.0% favorable effect of currency translation, due primarily to lower net sales of cough cold products stemming from lower incidence of cough cold throughout the E.U. compared to the prior year, as well as an unfavorable impact of 1.5% from divested businesses and exited product lines. These were partially offset by improved supply of key products, including the Physiomer® brand.Pain & Sleep-Aids: Net sales of $235.4 million increased 6.0%, inclusive of a 4.0% favorable effect of currency translation, due primarily to restored supply of the Solpadeine® brand.Healthy Lifestyle: Net sales of $231.5 million increased 2.5%, inclusive of a 0.6% favorable effect of currency translation, due primarily to new products in the Jungle Formula® franchise. VMS: Net sales of $161.2 million decreased 7.1%, inclusive of a 3.9% favorable effect of currency translation, due primarily to reduced strategic focus on nutraceutical products within the category.Women's Health: Net sales of $143.5 million increased 8.0%, inclusive of a 4.2% favorable effect of currency translation, due primarily to market share gains in ellaOne®.Oral Care: Net sales of $97.5 million decreased 2.0% inclusive of a 3.9% favorable effect of currency translation, due primarily to lower net sales of store brand products.Digestive Health and Other: Net sales of $102.7 million decreased 23.2%, inclusive of a 2.1% favorable effect of currency translation, due primarily to the divestiture of the Rare Diseases Business, partially offset by higher net sales of store brand digestive health products. TABLE IPERRIGO COMPANY PLCRECONCILIATION OF NON-GAAP MEASURES(in millions, except per share amounts)(unaudited)


Three Months Ended




Twelve Months Ended





December 31,
2025
December 31,
2024
Total Change
December 31,
2025
December 31,
2024
Total ChangeConsolidated Continuing Operations















Adjusted gross profit
$            401.1
$            423.9
$         22.8
(5.4) %
$        1,648.0
$        1,697.9
$        (49.9)
(2.9) %Adjusted gross margin
36.1 %
37.2 %


(110) bps
38.7 %
38.8 %


(10) bps
















Adjusted operating income
$            167.2
$            193.9
$        (26.7)
(13.8) %
$            622.3
$            608.5
$         13.8
2.3 %Adjusted operating margin
15.1 %
17.0 %


(200) bps
14.6 %
13.9 %


70 bps
















Adjusted net income
$            107.6
$            128.7
$        (21.1)
(16.4) %
$            381.6
$            354.0
$         27.6
7.8 %
















Adjusted EPS
$              0.77
$              0.93
$        (0.16)
(17.2) %
$              2.75
$              2.57
$         0.18
7.0 %
















Consumer Self-Care Americas















Adjusted gross profit
$            198.5
$            229.1
$        (30.6)
(13.4) %
$            801.8
$            828.6
$        (26.8)
(3.2) %Adjusted gross margin
28.5 %
30.8 %


(230) bps
31.0 %
30.8 %


30 bps
















Adjusted operating income
$            116.5
$            145.8
$        (29.3)
(20.1) %
$            410.7
$            421.9
$        (11.1)
(2.6) %Adjusted operating margin
16.7 %
19.6 %


(290) bps
15.9 %
15.7 %


20 bps































Consumer Self-Care International













Adjusted gross profit
$            202.7
$            194.4
$            8.3
4.2 %
$            846.4
$            869.1
$        (22.7)
(2.6) %Adjusted gross margin
49.1 %
49.3 %


(20) bps
50.8 %
51.7 %


(100) bps
















Adjusted operating income
$              89.6
$              83.4
$            6.1
7.4 %
$            365.3
$            352.1
$         13.1
3.7 %Adjusted operating margin
21.7 %
21.2 %


50 bps
21.9 %
21.0 %


90 bpsNote: Amounts may not add or recalculate due to rounding. Percentages are based on actuals.

(1)Currency impact is calculated using the exchange rates used to translate our financial statements in the comparable prior year period to show what current period US dollar results would have been if such currency exchange rates had not changed.(2)Represents divestiture of the Rare Diseases Business, Hospital and Specialty Business, Richard Bittner Business and branded asset sales in CSCI. 



View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-reports-fourth-quarter-and-fiscal-year-2025-financial-results-from-continuing-operations-302698253.htmlSOURCE Perrigo Company plc

Original: Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations

Perrigo to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026February 13, 2026 8:30 AM
PR Newswire (US)

DUBLIN, Feb. 13, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer health products, today announced that it plans to issue its fourth quarter and fiscal year 2025 financial results on Thursday, February 26th, 2026, and host a conference call beginning at 8:30 A.M. (EST).







The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 52719. A taped replay of the call will be available beginning at approximately 12:00 P.M. (EST) Thursday, February 26, until midnight Thursday, March 5, 2026. To listen to the replay, dial 888-660-6345, International 646-517-4150, and use access code 52719#.About PerrigoPerrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers trusted self-care solutions that can be used without the need for a prescription, ensuring accessibility and choice for consumers across molecules, dosage forms, and value tiers.Perrigo's unique business model leverages its complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.For more information, visit www.perrigo.com.Forward-Looking Statements This press release includes, and the matters discussed in Perrigo's upcoming earnings release will include certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements involve known and unknown risks, uncertainties and other factors—many of which are beyond the Company's control—that may cause the actual results, performance or achievements of the Company to be materially different from its current expectations, assumptions, estimates and projections. Interested persons are urged to consult the Company's filings with the United States Securities and Exchange Commission, available at https://investor.perrigo.com/sec-filings, for a discussion of the Company's business and financial condition and certain material trends, risks, uncertainties and other factors relating thereto, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2024.Perrigo ContactBradley Joseph, Vice President, Global Investor Relations, (269) 686-3373, E-mail: bradley.joseph@perrigo.comNicholas Gallagher, Associate Director, Global Investor Relations, (269) 686-3238, E-mail: nicholas.gallagher@perrigo.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-to-release-fourth-quarter-and-fiscal-year-2025-financial-results-on-february-26-2026-302687665.htmlSOURCE Perrigo Company plc

Original: Perrigo to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

Just got its over the counter birth control FDA approved a half hour ago !!!

Thanks PRGO

41.75 afterhours purchase

afterhours purchase above the high of the day

Why would this company invest in Kazmira?

Dividend helps starboard, but hurts the rest of the shareholders.....nobody is in this for a dividend! We want growth and profits

***NEWS OUT***

http://ih.advfn.com/p.php?pid=nmona&article=75174311&symbol=PRGO

Perrigo Launches The Generic Version Of Axiron® Topical Solution

DUBLIN, July 5, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the prescription pharmaceutical launch of testosterone topical solution, 30 mg/1.5 mL (CIII), the generic equivalent to Eli Lilly and Company's Axiron® Topical Solution, 30 mg/1.5 mL (CIII).

Axiron® Topical Solution, 30 mg/1.5 mL (testosterone topical solution, 30 mg/1.5 mL) is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Annual market sales for the 12 months ending April 2017 were approximately $248 million.

Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, "This is our third new product launch in the last two weeks. These new product launches illustrate our continued focus on developing and bringing to market important treatments in prescription extended topical therapeutic categories. The Rx team remains committed to investing in complex topical products and to launching more than five new products by the end of 2017."

About Perrigo

Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is the world's largest manufacturer of over-the-counter ("OTC") healthcare products and supplier of infant formulas for the store brand market. The Company also is a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of "extended topical" prescription drugs. Perrigo, headquartered in Ireland, sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China. Visit Perrigo online at (http://www.perrigo.com).

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the timing, amount and cost of any share repurchases; future impairment charges; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than we do; pricing pressures from customers and consumers; potential third-party claims and litigation, including litigation relating to our restatement of previously-filed financial information; potential impacts of ongoing or future government investigations and regulatory initiatives; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions, and our ability to realize the desired benefits thereof; our ability to achieve our guidance; our ability to execute and achieve the desired benefits of announced cost-reduction efforts and other initiatives; and the timing and expense to complete the announced tender offer for certain of our outstanding notes. In addition, the Company may identify and be unable to remediate one or more material weaknesses in its internal control over financial reporting. Furthermore, the Company and/or its subsidiaries may incur additional tax liabilities in respect of 2016 and prior years as a result of any restatement or may be found to have breached certain provisions of Irish company legislation in respect of prior financial statements and if so may incur additional expenses and penalties. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2016, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

I came in @.656 on the 24th...

One month later...

NICE!

You can't ask for a nicer progression upward!

Chart:

Indicators poised for the next leg up...

PRGO...

catching her breath...

Up... up... up...

Nice rise from .656 !!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=130821920

This is the kind of price action one likes to see...

slow and steady, with a little taken off the top from time to time...

and then...

reestablishing the climb...

NICE!

Best Dividend Paid in Over a Dozen Years!

http://ih.advfn.com/p.php?pid=nmona&article=74489043&symbol=PRGO

Nice, steady, upward movement for PRGO!

The stock has traded between $111.00 and $65.47 over the last 52-weeks, its 50-day SMA is now $72.19, and its 200-day SMA $83.38. Perrigo Company plc has a P/B ratio of 1.12

8-k Out

http://ih.advfn.com/p.php?pid=nmona&article=74417839&symbol=PRGO

Item of interest:

On April 7, 2017, the Company issued a notice of redemption to redeem all of the $600.0 million in aggregate principal amount of the outstanding 2.300% senior notes due 2018 (the “2.300% 2018 Notes”). The Company expects to redeem all of the 2.300% 2018 Notes on May 8, 2017 using proceeds from the sale of Tysabri

Perrigo Reaches Agreement With Auditor Over Royalty Accounting
Dublin drugmaker to restate financial statements as far back as Dec. 28, 2013

https://www.wsj.com/articles/perrigo-reaches-agreement-with-auditor-over-royalty-accounting-1493167564

Nice Timing!

**SMILES**

Daily volume doubling yesterday and already today...

Something in the works???

Nice upward movement in the past 2 days!

I came in @.656 on the 24th...

Let's see where this goes...

At a more than 50% discount, PRGO looks quite appetizing.

Anything new to get excited about?

IS Perrigo still, in your opinion, a buyout candidate, or perhaps, would they consider another alternative if their conditions cannot be met?

Anything in the wind?

*SNIFF* *SNIFF*

PRGO moving upward slowly...

3 Month PRGO Chart

Looking up...

Facebook Inc (NASDAQ:FB) Introduces New ‘Dislike’ Reaction Button On Messenger https://marketexclusive.com/facebook-inc-nasdaqfb-introduces-reaction-button-feature-messenger/79228/?icd1

Try Peregrine $PPHM. Avid Bioservices can even make biosimilars for you....




wook

This has been a welcomed couple of days. I've owned this since 2011 and will continue to own this through at least the next couple of years.

GSK consumer unit off the table it appears - http://www.telegraph.co.uk/business/2016/09/20/glaxosmithkline-names-emma-walmsley-to-replace-sir-andrew-witty/

Perrigo is becoming the Best viable option for several companies to acquire if they wish to expand in the US generics category.

We should get some meaningful news with PRGO soon


LONG PRGO.

PRGO - I'm buying the Rumor here, and settling in for the Long Haul

Van

PRGO - Reckitt Benckiser Buyout Potential


Pretty quiet here for a company that may get bought anytime....literally any Day. The puzzle pieces are fitting together way too well to be just a coincidence.


Timeline:

Back in 2015 Mylan tried to go hostile for Perrigo at a $180+ price tag, but did not succeed.

June of 2016 - Rumor hits the street of a Mystery UK buyer for PRGO at the $20B level.

July of 2016 - Rumor hits again that the UK buyer is Reckitt Benckiser of the UK, and preparing a $20B offer.

September 11th 2016 - Activist Starboard Value LP takes a 4.6% stake in PRGO, Advocating several actions within the company to Unlock Shareholder value.


Reckitt Benckiser has publicly looked at buying both Merek's Consumer health division, and Pfizer's Consumer division, but both of these are now off the table. Merek's sold to Bayer, and Pfizer is not breaking up the company until at least 2018. The Pfizer news just came out 6-days ago, so until then BR may have been waiting to see if that was a Viable option. Now it is not. There are far Fewer matches for RB now, than were possibly on the Table in 2014-2015. The clock is ticking for RB to make a move, and I think that they may make a bid for Perrigo before the new year.

My guess is RB has been kicking the Tires on Perrgio now for several months (since at least June), and waiting to see where the Dust settled on the Pfizer Breakup. RB was also mentioned as a buyer for Church & Dwight this Mayy, but those Rumors were Denied by Church & Dwight.

The last Rumor in June of this year even stated the financial Firms advising both PRGO and RB. This Seems awfully specific for an unfounded Rumor, and the June Rumor actually supports the RB theory, and the July story as well. Both Reckitt and Perrigo did NOT deny these Rumors.

Last month, a report claimed Perrigo was close to an agreement to be bought by a UK-based company for $US20bn, although it did not name the latter.

The report in StreetInsider.com cited a source as saying Morgan Stanley (NYSE:MS) was advising Perrigo and Barclays PLC (LON:BARC) was among institutions advising the UK company.


Reckitt Benckiser has been on the Acquisition hunt since at least 2014 to expand their Consumer Health division. They have not Purchased anything yet that fulfills that Goal.

RB CEO:
RB’s net debt ratio of 0.7 times adjusted earnings before interest, tax, depreciation and amortization is below that of competitors Unilever at 1.1 and Procter & Gamble Co. at 1.3, meaning the company has financial flexibility to pursue transformational acquisitions. Discussing firepower, Kapoor said that RB is not thinking about limitations on the size of a potential deal.

“If any of the interesting consumer-health assets were to come up today, I believe RB has the capacity to do it. Any of them,” he said.


With PRGO stock trading at $93 from a High of $200, with a shareholder base that is Angry regarding the slump in Stock Value, Perrigo is Ripe for a takeover bid in the $135-$160 range. The Rumor articles state that Perrigo is looking for a minimum of a 100% premium, but I don't believe if RB or another acquirer made their offer Public, it would take that elevated Premium to get it accomplished. With Starboard coming on board in the past 3-weeks, the Board and newer CEO will be under tremendous pressure to get the Share Price UP, and seriously consider any/all Major moves that may be good for the Stock Price.


Option Volume has been slightly unusual 3 days the past week, with Call Volume above normal, and directionally Bullish Action.

I continue to Add the Nov and Jan PRGO call options, along with the PRGO common stock which is Cheap whether the Perrigo Buyout with Reckitt occurs or not.

LONG PRGO !!!!!!!!!


Links:

http://www.fiercepharma.com/pharma/perrigo-up-for-20b-sale-to-mystery-u-k-buyer-report

http://www.proactiveinvestors.com/companies/news/128264/reckitt-benckiser-set-to-bid-for-perrigo-rumours-128264.html

http://www.modernhealthcare.com/article/20160926/NEWS/160929928

http://www.bloomberg.com/news/articles/2015-12-04/reckitt-benckiser-ceo-would-look-at-buying-pfizer-consumer-unit

http://www.fiercepharma.com/m-a/reckitt-benckiser-gives-up-on-merck-otc-deal-leaving-bayer-open-shot


http://www.cnbc.com/2016/05/19/church-dwight-shares-spike-amid-report-of-reckitt-benckiser-takeover-bid.html

http://thefly.com/news.php?symbol=PRGO


http://247wallst.com/healthcare-business/2015/06/01/3-specialty-pharma-stocks-that-could-be-acquired-in-2015/

Pfizer Drops plan to Breakup Company - PRGO on Deck for Reckitt

With Pfizer announcing plans that they will no longer breakup their Consumer Health division, another viable option for Reckitt has been taken off the table. My guess is they have been kicking the tires on both options for several months. In my estimation, there are fewer and fewer Consumer Health Divisions that fit the bill that Benckiser is looking to acquire.

This move may entice them to act, now that the other Potential target is off the table until at least 2018.

PRGO is in the Cross-hairs for them IMO :)

See Below.


http://www.iol.co.za/business/international/pfizer-drops-plan-to-break-up-company-2073247

http://www.bloomberg.com/news/articles/2015-12-04/reckitt-benckiser-ceo-would-look-at-buying-pfizer-consumer-unit

PRGO - I believe we get Big News here within a couple weeks. The UK buyer rumor is True in my Mind. Loading Call Options for Nov-Jan for a Big move UP. Options are trading TOO CHEAP for the buyout potential here.

Pretty Quiet on the Web about this stock.....I am surprised by that.

Van

I'm adding PRGO here. The stock is undervalued, and I believe the Takeover chatter from June and July is legitimate. The time for a buyer to strike is now while the stock is cheap, and the sector is experiencing major consolidation. A Perrigo Buyout is definitely a possibility. Reckitt Benckiser seems like a Good guess in my mind, as they have been on the Hunt for months, and picked up nothing major. Perrigo is a good fit for Reckitt

With Starboard taking a stake here, I think PRGO will have positive news within the next 4-weeks either way. They will make the BOD and Directors Unlock the True value of Perrigo. Adding PRGO Call Options and Perrigo Stock Daily.


Van

Reaction??

Interesting here :)

Nuts... High book value and earnings and fantasy for big bid to be sold to a great player
Tztztz...

Thanks

For you the same, did my "steals" yesterday,

Cheers

Always very quiet here only 20 posts in last 4 years

Seems like a great entry point at this level, pretty much at 2012/2013 lows and close to 50% off 52 week high.

I would say Up is the only direction to go from here as IMO selling was way overdone & really no major "issues".

Best to you. dp